Make notes of the content based on the katsungs clinical and medical pharmacology textbook, 16th edition. Also include all the main points and terms along with proper definitions. Make sure to include all the formulas, expressions properly just as it is given in the textbook. Make moderate length notes, neither too big nor too small notes. Make the notes usmle first aid based and MBBS level based as well.

Asking for Preferences

The goal of therapeutics is to achieve a desired beneficial effect with minimal adverse effects. When a medicine has been selected for a patient, the clinician must determine the dose that most closely achieves this goal. A rational approach to this objective combines the principles of pharmacokinetics with pharmacodynamics to understand the dose-effect relationship (Figure 3–1). Pharmaco- dynamics governs the concentration-effect part of the relationship, whereas pharmacokinetics deals with the dose-concentration part (Holford & Sheiner, 1981). The pharmacodynamic concepts of maximum response and sensitivity determine the magnitude of the effect at a particular concentration (see Emax and C50, Chapter 2; C50 is also known as EC50). The pharmacokinetic processes of input, distribution, and elimination determine how rapidly and for how long the target organ will be exposed to the drug. Figure 3–1 illustrates a fundamental hypothesis of pharmacol- ogy, namely, that a relationship exists between a beneficial or toxic effect of a drug and the concentration of the drug. This hypothesis has been documented for many drugs, as indicated by the target concentration column in Table 3–1. The target concentration is the concentration that reflects a balance between the beneficial and adverse effects. The apparent lack of such a relationship for some drugs does not weaken the basic hypothesis but points to the need to consider the time course of concentration at the actual site of pharmacologic effect (see below). Knowing the relationship between dose, drug concentration, and effects allows the clinician to take into account the various pathologic and physiologic features of a particular patient that make him or her different from the average individual in respond- ing to a drug. The importance of pharmacokinetics and pharma- codynamics in patient care thus rests upon the improvement in therapeutic benefit and reduction in toxicity that can be achieved by application of these principles. PHARMACOKINETICS The “standard” dose of a drug is based on trials in healthy subjects and patients with average ability to absorb, distribute, and eliminate the drug (see section Clinical Trials: The IND & NDA in Chapter 1). This dose will not be suitable for every patient. Several physiologic processes (eg, body size, maturation of organ function in neonates and infants) and pathologic processes (eg, heart failure, renal fail- ure) may be used for dosage adjustment in individual patients. Individual differences in these physiological and pathological processes are associated with specific pharmacokinetic and phar- macodynamic properties (usually referred to as parameters) of the drug. The two basic pharmacokinetic parameters are volume of distribution, the measure of the apparent space in the body avail- able to contain the drug, and clearance, the measure of the ability of the body to eliminate the drug. These parameters are illustrated schematically in Figure 3–2, where the volume of the beakers into which the drugs diffuse represents the volume of distribution, and the size of the outflow “drain” in Figures 3–2B and 3–2D represents the clearance. Volume of Distribution Volume of distribution (V) relates the amount of drug in the body to the concentration of drug (C) in blood or plasma: of the physical volumes of the body (Table 3–2). Volume of dis- tribution often exceeds any physical volume in the body because it is the volume apparently necessary to contain the amount of drug homogeneously at the concentration found in the blood, plasma, or water. Drugs with very high volumes of distribution have much higher concentrations in extravascular tissue than in the vascular compartment, ie, they are not homogeneously distributed. Drugs that are completely retained within the vas- cular compartment, on the other hand, would have a minimum possible volume of distribution equal to the plasma component in which they are distributed, eg, 0.04 L/kg body weight or 2.8 L/70 kg (see Table 3–2) for a drug that is restricted to the plasma compartment. Clearance Drug clearance concepts are similar to clearance concepts of renal physiology. Clearance of a drug is the factor that predicts the rate of elimination in relation to the drug concentration (C): (2) (1) The volume of distribution may be defined with respect to blood, plasma, or water (unbound drug), depending on the con- centration used in equation (1) (C = Cb, Cp, or Cu). That the V calculated from equation (1) is an apparent volume may be appreciated by comparing the volumes of distribution of drugs such as digoxin or chloroquine (see Table 3–1) with some Clearance, like volume of distribution, may be defined with respect to blood (CLb), plasma (CLp), or unbound in water (CLu), depending on where and how the concentration is measured. It is important to note the additive character of clearance. Elim- ination of drug from the body may involve processes occurring in the kidney, the lung, the liver, and other organs. Dividing the rate of elimination at each organ by the concentration of drug yields the respective clearance at that organ. Added together, these sepa- rate clearances equal total systemic clearance: (3a) (3b) (3c) (3d) “Other” tissues of elimination could include the lungs and additional sites of metabolism, eg, blood or muscle. The two major sites of drug elimination are the kidneys and the liver. Measurement of unchanged drug in the urine may be used to determine renal clearance. Within the liver, drug elimination occurs via biotransformation of parent drug to one or more metabolites, or excretion of unchanged drug into the bile, or both. Elimination of drug by the liver is difficult to measure directly, unlike renal elimi- nation, so hepatic clearance is often assumed to be the difference between total systemic clearance and renal clearance. The pathways of biotransformation are discussed in Chapter 4. For most drugs, clearance is constant over the concentration range encountered in clinical settings, ie, elimination is not saturable, and the rate of drug elimination is directly proportional to concentration (rearranging equation [2]): (4) When elimination is directly proportional to C, this is called first-order elimination. When clearance is first-order, it can be esti- mated by calculating the area under the curve (AUC) of the time- concentration profile after a dose. Clearance is calculated from the dose divided by the AUC. Note that this is a convenient form of calculation—not the definition of clearance. A. Capacity-Limited Elimination For drugs that exhibit capacity-limited elimination (eg, phenytoin, ethanol), clearance does not remain constant but will vary depend- ing on the concentration of drug that is achieved (see Table 3–1). Capacity-limited elimination is also known as mixed-order, satura- ble, nonlinear, and Michaelis-Menten elimination. It is associated with dose- or concentration-dependent clearance. Most drug elimination pathways by metabolism will become saturated if the dose and therefore the concentration are high enough. When blood flow to an organ does not limit elimination (see below), the relation between elimination rate and concentra- tion (C) is expressed mathematically in equation (5): The maximum elimination capacity is Vmax, and Km is the drug concentration at which the rate of elimination is 50% of Vmax. At concentrations that are high relative to the Km, the elimination rate is almost independent of concentration—a state of “pseudo- zero order” elimination. If dosing rate exceeds elimination capac- ity, steady state cannot be achieved. The concentration will keep on rising as long as dosing continues. This pattern of capacity- limited elimination is important for three drugs in common use: ethanol, phenytoin, and aspirin. Clearance has no real meaning for drugs with capacity-limited elimination because it varies with concentration, and AUC should not be used to calculate clearance of such drugs. B. Flow-Dependent Elimination In contrast to capacity-limited drug elimination, some drugs are cleared very readily by the organ of elimination, so that at any clinically realistic concentration of the drug, most of the drug in the blood perfusing the organ is eliminated on the first pass of the drug through the organ. The elimination of these drugs will thus depend primarily on the rate of drug delivery to the organ of elimi- nation. Such drugs (see Table 4–7) can be called “high-extraction” drugs since they are almost completely extracted from the blood by the organ. Blood flow to the organ is the main determinant of drug delivery, but plasma protein binding and blood cell partition- ing may also be important for extensively bound drugs that are highly extracted. C. Large Molecules There are two aspects to the pharmacokinetics of proteins, often referred to as large molecules, when used as therapeutic agents. The first is that they all have much the same pharmacokinetics with a half-life of a couple of weeks. The second is that for some, but not all, the effect of the molecule is produced by binding to the target site. Elimination of the molecule is to some extent determined by the elimination of the target (eg, T cells). This is called target-medi- ated drug disposition. When target-mediated disposition occurs, the clearance of the molecule is increased and the half-life gets shorter. The time course of the effect of the molecule often follows the resulting changes in the time course of drug concentration. Half-Life Half-life (t1/2) is the time required to change the amount of drug in the body by one-half during elimination (or during a constant infusion). In the simplest case—and the most useful in designing drug dosage regimens—the body may be considered as a single compartment (as illustrated in Figure 3–2B) of a size equal to the volume of distribution (V). The time course of drug in the body will depend on both the volume of distribution and the clearance: Because drug elimination can be described by an exponential process, the time taken for a twofold decrease can be shown to be proportional to the natural logarithm of 2. The constant 0.7 in equation (6) is an approximation to the natural logarithm of 2. The elimination half-life is useful because it indicates the time required to attain 50% of steady state—or to decay 50% from steady-state conditions—after a change in the rate of drug input. Figure 3–3 shows the time course of drug accumulation during a constant-rate drug infusion and the time course of drug elimina- tion after stopping an infusion that has reached steady state. Disease states can affect both of the physiologically related primary pharmacokinetic parameters: volume of distribution and clearance. A change in elimination half-life will not necessarily reflect a change in drug elimination. For example, patients with chronic renal failure have both decreased renal clearance of digoxin and a decreased volume of distribution; the increase in digoxin elimination half-life is not as great as might be expected based on the change in renal function. The decrease in volume of distribu- tion is due to the decreased renal and skeletal muscle mass and consequent decreased tissue binding of digoxin to Na+/K+-ATPase. Many drugs will exhibit multicompartment pharmacokinetics (as illustrated in Figures 3–2C and 3–2D). Under these condi- tions, the “half-life” describing drug accumulation, as given in Table 3–1, will be greater than that calculated from equation (6).

Reading File

Finding Sources

The user has pasted the textbook content directly. I have enough material to write thorough notes. Let me proceed directly from the provided text.

📘 Pharmacokinetics - Chapter 3 Notes

Katzung's Basic & Clinical Pharmacology, 16th Edition

(USMLE First Aid + MBBS Level)

1. CORE CONCEPT: Dose-Effect Relationship

Goal of therapeutics: Achieve maximum beneficial effect with minimal adverse effects.

The dose-effect relationship is governed by two principles:

Domain	What it governs
Pharmacodynamics (PD)	Concentration → Effect relationship
Pharmacokinetics (PK)	Dose → Concentration relationship

PD determines the magnitude of effect at a given concentration (defined by E_max and C50/EC50)
PK (input, distribution, elimination) determines how fast and how long the target organ is exposed to the drug

Target Concentration = the drug concentration that best balances beneficial vs. adverse effects (See Table 3-1 in textbook)

2. THE TWO BASIC PK PARAMETERS

A. Volume of Distribution (V or Vd)

Definition: The apparent volume of body fluid required to contain the total amount of drug at the same concentration as found in plasma/blood.

$$V = \frac{\text{Amount of drug in body}}{\text{Concentration of drug (C)}}$$

Equation (1): $$V_d = \frac{\text{Amount of drug in body}}{C}$$

Where C can be measured as:

C_b = blood concentration
C_p = plasma concentration
C_u = unbound (free) drug concentration in water

Key Points:

Vd is an apparent (not real) volume - it does not correspond to a real anatomical space
Vd often exceeds any physical body volume - this happens when drug concentrates in extravascular tissues
A high Vd = drug preferentially distributes into tissues (e.g., digoxin, chloroquine)
A low Vd = drug stays in the vascular compartment

Physical Compartment Reference Values (Table 3-2):

Compartment	Volume (L/70 kg)
Plasma	~2.8 L (0.04 L/kg)
Blood	~5.6 L
Extracellular fluid	~14 L
Total body water	~42 L

USMLE Pearl: If Vd is very large (e.g., digoxin ~500 L), hemodialysis is NOT effective at removing the drug because most of it is outside the plasma compartment.

B. Clearance (CL)

Definition: The factor that predicts the rate of elimination in relation to drug concentration.

Equation (2): $$\text{Rate of elimination} = CL \times C$$

Or rearranged: $$CL = \frac{\text{Rate of elimination}}{C}$$

Clearance is additive - organs contribute their own clearances to total systemic clearance

Equation (3a-3d): $$CL_{total} = CL_{renal} + CL_{hepatic} + CL_{other}$$

Where:

CL_renal = measured from unchanged drug in urine
CL_hepatic = assumed = CL_total - CL_renal (difficult to measure directly)
CL_other = lungs, blood, muscle, etc.

First-Order Elimination (most drugs): $$\text{Rate of elimination} = CL \times C \quad \text{(Equation 4)}$$

Clearance is constant over clinically relevant concentrations
Elimination is directly proportional to concentration → first-order kinetics
CL can be estimated as: $$CL = \frac{\text{Dose}}{AUC}$$

(AUC = area under the concentration-time curve; this is a calculation convenience, not the definition)

3. TYPES OF ELIMINATION

A. Capacity-Limited (Saturable / Michaelis-Menten) Elimination

Also called: Mixed-order, nonlinear, zero-order (at saturation), Michaelis-Menten elimination

Equation (5) - Michaelis-Menten: $$\text{Rate of elimination} = \frac{V_{max} \times C}{K_m + C}$$

Parameter	Definition
V_max	Maximum elimination capacity
K_m	Drug concentration at which elimination rate = 50% of V_max

Behavior at different concentrations:

Concentration vs K_m	Kinetics	Behavior
C << K_m	First-order	Rate ∝ C
C >> K_m	Pseudo-zero-order	Rate ≈ constant (≈ V_max), independent of C

Critical Drugs with Capacity-Limited Elimination:

Ethanol

Phenytoin

Aspirin (at high doses)

USMLE Pearl: For phenytoin - small dose increases → disproportionately large rise in plasma concentration due to saturable metabolism. AUC should NOT be used to calculate clearance for these drugs.

If dosing rate exceeds elimination capacity → steady state cannot be achieved → concentration rises indefinitely.

B. Flow-Dependent (High-Extraction) Elimination

Drugs are so efficiently extracted by the organ that most drug is cleared on the first pass
Elimination depends primarily on blood flow to the organ (not enzyme capacity)
Plasma protein binding and red blood cell partitioning also matter for highly bound drugs
These are called "high-extraction" drugs

Example: Lidocaine, morphine, propranolol (high hepatic extraction - see Table 4-7)

C. Large Molecules (Biologics/Proteins)

Most therapeutic proteins share similar PK with a half-life of ~2 weeks
Some act by binding to target sites; elimination is partly determined by target elimination
This is called Target-Mediated Drug Disposition (TMDD)
- When TMDD occurs → clearance increases → half-life shortens
- Effect time course mirrors drug concentration time course

4. HALF-LIFE (t½)

Definition: Time required to change the amount of drug in the body by one-half during elimination (or during constant infusion).

Equation (6): $$t_{1/2} = \frac{0.7 \times V}{CL}$$

0.7 ≈ natural logarithm of 2 (ln 2 = 0.693)
V = volume of distribution
CL = clearance

Key Relationships:

t½ increases if V increases (drug distributes more widely)
t½ decreases if CL increases (drug eliminated faster)
t½ is not an independent parameter - it is derived from V and CL

Clinical Uses of Half-Life:

Use	Rule
Time to reach steady state	~4-5 × t½ (50% at 1× t½)
Time to decay from steady state	~4-5 × t½ after stopping
Dosing interval guidance	Usually ~1 t½

Disease Effects on t½ - Important Example:

In chronic renal failure with digoxin:
- Renal CL is decreased → would increase t½
- BUT Vd also decreases (due to decreased renal and skeletal muscle mass → less Na⁺/K⁺-ATPase binding)
- Net result: t½ increase is less than expected from the CL decrease alone

USMLE Pearl: A change in t½ does NOT always reflect a change in drug elimination - you must assess both V and CL independently.

5. MULTICOMPARTMENT PHARMACOKINETICS

Many drugs show multicompartment behavior (not a single compartment)
The observed half-life during accumulation (Table 3-1) may be greater than the half-life calculated from equation (6)
Distribution phase (alpha phase) + elimination phase (beta phase) can be distinguished graphically

6. SUMMARY TABLE - Key Formulas

Formula	Equation
Volume of Distribution	V = Amount of drug / C
Rate of Elimination	Rate = CL × C
Total Clearance	CL_total = CL_renal + CL_hepatic + CL_other
Clearance from AUC	CL = Dose / AUC
Michaelis-Menten	Rate = (V_max × C) / (K_m + C)
Half-life	t½ = (0.7 × V) / CL

7. USMLE HIGH-YIELD MNEMONICS & PEARLS

"PAD" - Pharmacokinetics = Absorption, Distribution, Elimination (the Dose-Concentration link)
High Vd = drug trapped in tissues = dialysis won't work
Phenytoin, Ethanol, Aspirin (PEA) = zero-order / capacity-limited kinetics
t½ = 0.7 × V / CL - memorize this; both V and CL affect half-life
First-order: constant fraction eliminated per unit time; Zero-order: constant amount eliminated per unit time
4-5 half-lives to reach or leave steady state (applies only to first-order drugs)
High-extraction drugs (e.g., lidocaine, morphine) - hepatic blood flow changes (e.g., in heart failure) dramatically alter their clearance
TMDD (biologics): target level regulates drug clearance - as target is depleted, clearance slows and half-life lengthens

8. CLINICAL RELEVANCE SUMMARY

Clinical Scenario	Affected PK Parameter	Consequence
Renal failure	↓ CL_renal	↑ drug accumulation
Heart failure	↓ hepatic blood flow	↓ CL of high-extraction drugs
Obesity	↑ V for lipophilic drugs	Prolonged t½
Neonates / infants	Immature CL	Drug accumulation
Chronic renal failure + digoxin	↓ CL and ↓ V	t½ change less dramatic than expected

Source: Katzung's Basic and Clinical Pharmacology, 16th Edition - Chapter 3: Pharmacokinetics & Pharmacodynamics

Make notes on chapter 3: Pharmacokinetics & Pharmacodynamics: Rational Dosing & the Time Course from katsung of Drug Action

Finding Sources

Reading File

📖 Chapter 3: Pharmacokinetics & Pharmacodynamics - Rational Dosing & the Time Course of Drug Action

Katzung's Basic & Clinical Pharmacology, 16th Edition

USMLE First Aid + MBBS Level Notes

SECTION 1: CORE FRAMEWORK

Goal of therapeutics: Maximum beneficial effect + minimal adverse effects.

The dose-effect relationship is split into two domains:

Domain	Governs	Key Parameters
Pharmacokinetics (PK)	Dose → Concentration	Input, Distribution, Elimination
Pharmacodynamics (PD)	Concentration → Effect	E_max, C50 / EC50

Concentration is the critical link between PK and PD - it is the focus of rational dosing.

Target Concentration (TC): The drug concentration that best balances beneficial vs. adverse effects. Varies by therapeutic goal (e.g., digoxin: 1 ng/mL for heart failure, 2 ng/mL for atrial fibrillation).

SECTION 2: THE TWO PRIMARY PK PARAMETERS

A. Volume of Distribution (V or Vd)

Definition: The apparent volume needed to contain the total amount of drug in the body at the same concentration as measured in blood or plasma.

$$\boxed{V = \frac{\text{Amount of drug in body}}{C} \quad \text{...(Eq. 1)}}$$

C can be blood (C_b), plasma (C_p), or unbound/free drug in water (C_u)
Vd is apparent - it does NOT represent a real anatomical space

Physical reference volumes (Table 3-2):

Body Compartment	Volume
Plasma	0.04 L/kg (~2.8 L/70 kg)
Blood	~5.6 L/70 kg
Extracellular fluid	~14 L/70 kg
Total body water	~42 L/70 kg

Interpreting Vd:

Vd	Meaning	Example drugs
Small (~3-5 L)	Stays in plasma; large molecule or highly protein-bound	Heparin, warfarin
Moderate (~14 L)	Distributes to ECF	Aminoglycosides
Large (>42 L)	Concentrates in tissues	Digoxin (~500 L), Chloroquine
Very large (hundreds of L)	Extensive tissue binding	Amiodarone

USMLE Pearl: High Vd = drug is mostly in tissues = dialysis is INEFFECTIVE at removing it.

B. Clearance (CL)

Definition: The factor that predicts the rate of drug elimination relative to concentration.

$$\boxed{CL = \frac{\text{Rate of elimination}}{C} \quad \text{...(Eq. 2)}}$$

Rearranged: Rate of elimination = CL × C

Clearance is additive across organs:

$$\boxed{CL_{total} = CL_{renal} + CL_{hepatic} + CL_{other} \quad \text{...(Eq. 3a-3d)}}$$

"Other" = lungs, blood, muscle
Renal CL = measured from unchanged drug in urine
Hepatic CL = assumed = CL_total − CL_renal (hard to measure directly)

For first-order drugs:

$$\boxed{CL = \frac{\text{Dose}}{AUC} \quad \text{...(Eq. 4 rearranged)}}$$

(This is a calculation convenience, not the definition of clearance.)

First-order elimination: Rate of elimination is directly proportional to C. CL remains constant. A constant fraction is eliminated per unit time.

SECTION 3: TYPES OF ELIMINATION

A. Capacity-Limited (Michaelis-Menten) Elimination

Also called: Saturable / nonlinear / mixed-order / zero-order (at saturation) elimination

$$\boxed{\text{Rate of elimination} = \frac{V_{max} \times C}{K_m + C} \quad \text{...(Eq. 5)}}$$

Parameter	Definition
V_max	Maximum elimination capacity of the enzyme system
K_m	Drug concentration at which elimination rate = 50% of V_max

Concentration-dependent behavior:

Concentration vs K_m	Kinetics	Clinical Result
C << K_m	First-order (linear)	CL appears constant
C ≈ K_m	Mixed order	Transitional
C >> K_m	Pseudo-zero order	Rate ≈ V_max; constant amount eliminated per unit time

Key rules for capacity-limited drugs:

If dosing rate exceeds elimination capacity → steady state is never reached; concentration rises indefinitely
CL has no real meaning (varies with concentration)
AUC must NOT be used to calculate CL for these drugs

The 3 classic capacity-limited drugs (PEA):

Phenytoin

Ethanol

Aspirin (at toxic/anti-inflammatory doses)

B. Flow-Dependent (High-Extraction) Elimination

Drug is so efficiently cleared that most is eliminated on the first pass through the organ
Elimination rate depends primarily on blood flow, not enzyme capacity
Called "high-extraction drugs"
Plasma protein binding and red blood cell partitioning can also be important for extensively bound high-extraction drugs

Examples: Lidocaine, morphine, propranolol, nitroglycerin Clinical implication: In heart failure (↓ hepatic blood flow) → CL of these drugs falls dramatically → toxicity risk ↑

C. Large Molecules (Biologics / Therapeutic Proteins)

Shared PK: half-life of approximately 2 weeks
Some cause Target-Mediated Drug Disposition (TMDD) - when the drug binds and eliminates the target (e.g., T cells), the target also contributes to drug clearance
When TMDD occurs: CL increases → t½ shortens
As target is depleted over time: CL slows → t½ lengthens
Effect time course mirrors changes in drug concentration

SECTION 4: HALF-LIFE (t½)

Definition: Time required to change the amount of drug in the body by one-half during elimination (or during constant infusion).

$$\boxed{t_{1/2} = \frac{0.7 \times V}{CL} \quad \text{...(Eq. 6)}}$$

0.7 ≈ ln 2 = 0.693 (exact)
t½ is a derived (secondary) parameter - depends on both V and CL
t½ increases when V ↑ or CL ↓

Time to steady state / elimination:

Half-lives elapsed	% Steady state reached	% Remaining after stopping
1	50%	50%
2	75%	25%
3	87.5%	12.5%
4	93.75%	~6%
5	~97%	~3% ← clinically = complete

USMLE Rule: ~4-5 half-lives to reach or leave steady state.

Key insight: A change in t½ does NOT always reflect a change in drug elimination. Both V and CL must be assessed independently.

Classic example - Digoxin in chronic renal failure:

CL ↓ (would lengthen t½)

V also ↓ (↓ skeletal muscle mass → ↓ Na⁺/K⁺-ATPase binding)

Net: t½ increase is less than expected from CL change alone

SECTION 5: DRUG ACCUMULATION & ACCUMULATION FACTOR

$$\boxed{\text{Accumulation factor} = \frac{1}{1 - e^{-0.7 \times \frac{\text{Dosing interval}}{t_{1/2}}}} \quad \text{...(Eq. 7)}}$$

For a drug dosed once every half-life: accumulation factor = 1/0.5 = 2
Predicts ratio of steady-state concentration to concentration after first dose
Peak concentrations at steady state = (Peak after first dose) × accumulation factor

SECTION 6: BIOAVAILABILITY (F)

Definition: Fraction of unchanged drug reaching the systemic circulation after administration by any route.

$$\boxed{F = \frac{AUC_{oral}}{AUC_{IV}} \times \frac{Dose_{IV}}{Dose_{oral}}}$$

Routes and bioavailability (Table 3-3):

Route	Bioavailability	Key Feature
IV	100% (by definition)	Most rapid onset
IM	75 to ≤100%	Large volumes feasible; may be painful
SC	75 to ≤100%	Smaller volumes than IM
Oral (PO)	5 to <100%	Most convenient; first-pass effect important
Rectal (PR)	30 to <100%	Less first-pass effect than oral
Inhalation	5 to <100%	Very rapid onset
Transdermal	80 to ≤100%	Slow absorption; avoids first-pass; prolonged action

Two reasons oral F < 100%:

Incomplete absorption across the gut wall
First-pass elimination by the liver

First-pass effect: Drug absorbed from gut → portal vein → liver → extensive hepatic metabolism before reaching systemic circulation. Reduces effective dose significantly.

Examples of high first-pass drugs: nitroglycerin, morphine, propranolol, lidocaine

SECTION 7: DRUG INPUT - RATE & EXTENT

Extraction Ratio (ER)

$$ER = \frac{CL_{hepatic}}{Q_{liver}}$$

Where Q_liver = hepatic blood flow (~90 L/h/70 kg)

High ER (>0.7): Flow-limited; oral bioavailability poor; CL ≈ hepatic blood flow
Low ER (<0.3): Capacity-limited; oral bioavailability good; CL independent of blood flow

Oral Bioavailability with First-Pass:

$$F = F_{abs} \times (1 - ER)$$

SECTION 8: THE TIME COURSE OF DRUG ACTION

A. Effect Compartment Concept

For drugs with a delay between plasma concentration and effect, the drug must first reach the effect site (biophase)
Example: IV digoxin - full cardiac effect takes ~6 hours despite rapid peak plasma levels because distribution to myocardium takes time

B. Slow Turnover Effects (Indirect Effects)

Drugs that affect biosynthesis or degradation of an endogenous substance show delayed effects
Warfarin example:
- Warfarin inhibits vitamin K epoxide reductase (VKOR) rapidly
- BUT the clinical effect (↑ INR) is delayed because it reflects depletion of prothrombin complex clotting factors
- Clotting factor complex has t½ ≈ 14 hours
- This t½ determines the rate of onset of anticoagulant effect, NOT the t½ of warfarin itself

C. Schedule-Dependent Effects

Example: Aminoglycosides (gentamicin)
- Constant infusion → greater renal toxicity than intermittent dosing
- Even with same average steady-state concentration
- Intermittent dosing → high peaks → saturate renal cortex uptake mechanism → less total accumulation
- Once-daily dosing is preferred to exploit this saturable uptake
- Related to: reversible drug action + nonlinear concentration-response relationship

D. Cumulative Effects

Some effects correlate with total cumulative exposure (AUC), not peak concentrations
Example: Cytotoxic chemotherapy drugs that bind irreversibly to DNA
- Effect on tumor = cumulative drug-DNA binding
- AUC is the appropriate PK target for dose individualization

SECTION 9: TARGET CONCENTRATION APPROACH TO RATIONAL DOSING

Maintenance Dose

$$\boxed{\text{Dosing rate} = CL \times TC \quad \text{...(Eq. 8)}}$$

$$\boxed{\text{Maintenance dose} = \frac{CL \times TC \times \text{Dosing interval}}{F}}$$

At steady state: rate in = rate out
CL is the most important PK parameter for maintenance dosing
F (bioavailability) must be included for non-IV routes

Worked example (digoxin in elderly woman): Use Cockcroft-Gault to estimate CrCl → estimate renal CL → calculate maintenance dose = CL × TC / F

Loading Dose

$$\boxed{\text{Loading dose} = \frac{V \times TC}{F} \quad \text{...(Eq. 9)}}$$

Used when therapeutic effect is needed rapidly (cannot wait 4-5 t½)
V is the key PK parameter for loading dose (not CL)
If Vd is large → large loading dose required
Given as a single dose or divided doses to avoid toxicity

Example: Digoxin loading ("digitalization"): given in divided doses over 12-24 hours because of the large Vd and narrow therapeutic index.

SECTION 10: PHARMACODYNAMICS TO DOSE INDIVIDUALIZATION

Key PK Parameters Needed:

Parameter	Role in dosing
Clearance (CL)	Determines maintenance dose
Volume of distribution (V)	Determines loading dose
Half-life (t½)	Determines dosing interval and time to steady state
Bioavailability (F)	Scaling factor for oral doses

Key PD Parameters Needed:

Parameter	Definition
E_max	Maximum achievable drug effect
C50 (EC50)	Concentration producing 50% of E_max

SECTION 11: THERAPEUTIC DRUG MONITORING (TDM)

When to Use TDM:

Narrow therapeutic index drugs (digoxin, lithium, phenytoin, aminoglycosides, cyclosporine)
Suspected toxicity or treatment failure
Disease states affecting PK (renal failure, liver failure, obesity)
Suspected non-compliance

Factors That Affect Drug Concentration Measurements:

1. Binding to plasma proteins:

Many drugs are bound to albumin (acidic drugs) or alpha-1-acid glycoprotein (basic drugs)
Only free (unbound) drug is pharmacologically active
In hypoalbuminemia (liver disease, nephrotic syndrome): total concentration falls, but free (active) concentration may be unchanged
Clinical relevance: When plasma proteins are low, total drug concentration will be lower but unbound concentrations are not affected

2. Plasma protein binding - Is it clinically important?

Protein binding displacement alone does NOT cause clinically significant toxicity
The body is an open system - increased free drug → increased elimination → concentration returns to previous steady state within ~4 half-lives
When protein-binding displacement does cause toxicity, the displacing drug is also inhibiting clearance - it is the CL change that matters

3. Binding to red blood cells:

Drugs like cyclosporine and tacrolimus bind extensively inside RBCs
Whole blood concentrations (~50x higher than plasma)
A fall in hematocrit → whole blood concentration falls, but pharmacologically active concentration is unchanged

Timing of Blood Samples for TDM:

Drug	Sampling time
Most oral drugs	At least 2 hours after dose (wait for absorption to complete)
Digoxin	At least 6 hours after dose (allow distribution to tissues)
Lithium	Just before next dose (trough; usually 24 hours after last dose)
Aminoglycosides	At least 1 hour after dose

Rule: Clearance is estimated from dosing rate and mean steady-state concentration. Volume of distribution is estimated from concentration at time zero after IV bolus.

SECTION 12: SPECIAL PHARMACOKINETIC SCENARIOS

Renal Failure

↓ CL_renal → drug accumulates
Adjust maintenance dose (reduce dose or increase interval)
Loading dose usually unchanged (V unaffected unless edema/fluid shifts)
Use creatinine clearance (CrCl) to estimate renal function:

$$\boxed{CrCl = \frac{(140 - \text{Age}) \times \text{Weight (kg)}}{72 \times \text{Serum creatinine (mg/dL)}} \times 0.85 \text{ (if female)}}$$

Hepatic Disease (Cirrhosis)

↓ plasma CL + ↑ Vd → t½ can increase threefold or more
High-extraction drugs especially affected (CL tied to hepatic blood flow)
Hypoalbuminemia alters protein binding but unbound drug concentration is preserved (see above)

Heart Failure

↓ hepatic blood flow → ↓ CL of high-extraction drugs (lidocaine, morphine)
Edema → ↑ Vd for water-soluble drugs

Elderly Patients

↓ renal function (even with "normal" creatinine, as muscle mass is reduced)
Diazepam example: CL does NOT change with age, but V increases → longer t½

Neonates and Infants

Immature organ function → decreased CL
Standard adult doses cause toxicity

SECTION 13: SUMMARY OF KEY FORMULAS

Formula	Equation
Volume of distribution	$V = \dfrac{\text{Amount of drug in body}}{C}$
Clearance	$CL = \dfrac{\text{Rate of elimination}}{C}$
Total clearance	$CL_{total} = CL_{renal} + CL_{hepatic} + CL_{other}$
Clearance (from AUC)	$CL = \dfrac{\text{Dose}}{AUC}$
Michaelis-Menten kinetics	$\text{Rate} = \dfrac{V_{max} \times C}{K_m + C}$
Half-life	$t_{1/2} = \dfrac{0.7 \times V}{CL}$
Accumulation factor	$\dfrac{1}{1 - e^{-0.7 \times \frac{\tau}{t_{1/2}}}}$
Maintenance dose	$\dfrac{CL \times TC \times \tau}{F}$
Loading dose	$\dfrac{V \times TC}{F}$
Oral bioavailability (first-pass)	$F = F_{abs} \times (1 - ER)$

SECTION 14: HIGH-YIELD USMLE MNEMONICS

Mnemonic	What it covers
PEA	Phenytoin, Ethanol, Aspirin = zero-order / capacity-limited kinetics
CL = Dose/AUC	First-order drugs only; not for PEA drugs
"4-5 half-lives"	Time to reach or leave steady state
Loading = V × TC / F	V determines loading dose
Maintenance = CL × TC / F	CL determines maintenance dose
High Vd = dialysis fails	Drug is in tissues, not accessible in blood
High ER + heart failure	Blood flow ↓ → CL ↓ → toxicity
Warfarin delay	INR effect delayed by clotting factor t½ (~14 h), not warfarin t½
Aminoglycoside OD dosing	High peak saturates renal uptake → less nephrotoxicity

SECTION 15: QUICK-RECALL TABLE - KEY DRUGS (Table 3-1 Highlights)

Drug	CL	Vd	t½	Target Concentration	Notes
Digoxin	Low renal CL	Very large (~500 L)	~39 h	1-2 ng/mL	↓ both CL and Vd in renal failure
Phenytoin	Capacity-limited	45 L	Variable	10-20 mg/L	Zero-order; small dose changes → big [C] changes
Lithium	Renal CL	~50 L	~22 h	0.6-1.2 mEq/L	No protein binding; distributes like Na⁺
Warfarin	Hepatic CL	9 L	~37 h	INR-guided	Protein-bound; CYP2C9 metabolism
Aminoglycosides	Renal CL	18 L	~2-3 h	Peak & trough	Nephrotoxic; once-daily preferred
Cyclosporine	Hepatic; binds RBCs	Large	~6-12 h	100-400 ng/mL	Measure in whole blood
Diazepam	Hepatic CL	Increases with age	~43 h	-	Age ↑ Vd, not CL

Source: Katzung's Basic and Clinical Pharmacology, 16th Edition - Chapter 3: Pharmacokinetics & Pharmacodynamics: Rational Dosing & the Time Course of Drug Action

I cannot see the equations clearly

Here are all the equations written out in plain, clearly readable text format:

📐 All Equations - Chapter 3 (Katzung 16th Ed.)

Written in plain text for maximum clarity

EQUATION 1 — Volume of Distribution

        Amount of drug in body
Vd  =  ────────────────────────
          Concentration (C)

EQUATION 2 — Clearance

           Rate of elimination
CL  =  ────────────────────────
              C

  OR rearranged:

  Rate of elimination  =  CL × C

EQUATION 3 — Total Clearance (Additive)

CL(total)  =  CL(renal)  +  CL(hepatic)  +  CL(other)

EQUATION 4 — Clearance from AUC (First-Order Only)

          Dose
CL  =  ─────────
          AUC

(Calculation convenience only — not the definition of clearance. Valid for first-order drugs ONLY — NOT for phenytoin, ethanol, or aspirin)

EQUATION 5 — Michaelis-Menten (Capacity-Limited) Elimination

                    Vmax  ×  C
Rate of elimination  =  ──────────────
                      Km  +  C

Where:

Vmax = maximum elimination capacity
Km = concentration at which elimination rate = 50% of Vmax
When C >> Km → rate ≈ Vmax → pseudo-zero-order (constant amount eliminated)
When C << Km → rate ∝ C → behaves like first-order

EQUATION 6 — Half-Life

          0.7  ×  V
t(1/2)  =  ──────────
               CL

Where:

0.7 = approximation of ln(2) = 0.693
V = volume of distribution
CL = clearance

EQUATION 7 — Accumulation Factor

                           1
Accumulation factor  =  ─────────────────────────────────
                         1  −  e^(−0.7 × τ / t½)

Where τ (tau) = dosing interval

When dosing interval = 1 half-life:

  Accumulation factor  =  1 / 0.5  =  2

EQUATION 8 — Maintenance Dose

                    CL  ×  TC  ×  τ
Maintenance dose  =  ─────────────────
                           F

Where:

CL = clearance
TC = target concentration
τ = dosing interval
F = bioavailability (= 1 for IV)

Simplified (dosing rate at steady state):

  Dosing rate  =  CL  ×  TC

EQUATION 9 — Loading Dose

                  V  ×  TC
Loading dose  =  ──────────
                     F

Where:

V = volume of distribution
TC = target concentration
F = bioavailability

EQUATION 10 — Oral Bioavailability with First-Pass Effect

  F  =  F(abs)  ×  (1 − ER)

Where:

F(abs) = fraction absorbed from the gut
ER = extraction ratio = CL(hepatic) / Q(liver)
Q(liver) = hepatic blood flow (~90 L/h/70 kg)

EQUATION 11 — Creatinine Clearance (Cockcroft-Gault)

        (140 − Age)  ×  Weight (kg)
CrCl  =  ────────────────────────────  ×  0.85  (for females)
           72  ×  Serum Creatinine
                    (mg/dL)

EQUATION 12 — Half-Life to Steady State

  % Steady state reached  =  1  −  (0.5)^n

  where n = number of half-lives elapsed

Half-lives (n)	% Steady State
1	50%
2	75%
3	87.5%
4	93.8%
5	~97% (clinically = complete)

QUICK REFERENCE — What Each Parameter Controls

  MAINTENANCE DOSE  →  driven by  CL  (clearance)
  LOADING DOSE      →  driven by  V   (volume of distribution)
  TIME TO PLATEAU   →  driven by  t½  (half-life)
  DOSE ADJUSTMENT   →  driven by  F   (bioavailability)

All equations from Katzung's Basic & Clinical Pharmacology, 16th Ed., Chapter 3

Include the equations in the notes above.

Here are the complete notes with all equations embedded in plain text format throughout:

📖 Chapter 3: Pharmacokinetics & Pharmacodynamics — Rational Dosing & the Time Course of Drug Action

Katzung's Basic & Clinical Pharmacology, 16th Edition

USMLE First Aid + MBBS Level Notes

SECTION 1: CORE FRAMEWORK

Goal of therapeutics: Maximum beneficial effect + minimal adverse effects.

The dose-effect relationship is split into two domains:

Domain	Governs	Key Parameters
Pharmacokinetics (PK)	Dose → Concentration	Input, Distribution, Elimination
Pharmacodynamics (PD)	Concentration → Effect	E_max, C50 / EC50

Concentration is the critical link between PK and PD — it is the focus of the Target Concentration Approach to rational dosing.

Target Concentration (TC): The drug concentration that best balances beneficial vs. adverse effects.

Example: Digoxin — 1 ng/mL for heart failure; 2 ng/mL for atrial fibrillation

SECTION 2: THE TWO PRIMARY PK PARAMETERS

A. Volume of Distribution (V or Vd)

Definition: The apparent volume needed to contain the total amount of drug in the body at the same concentration as measured in blood or plasma.

EQUATION 1:

        Amount of drug in body
Vd  =  ────────────────────────
           Concentration (C)

C may be blood (Cb), plasma (Cp), or unbound/free water (Cu)
Vd is apparent — it does NOT represent a real anatomical space
Vd often exceeds any physical volume because drug concentrates in tissues

Physical reference volumes (Table 3-2):

Compartment	Volume
Plasma	0.04 L/kg (~2.8 L/70 kg)
Blood	~5.6 L/70 kg
Extracellular fluid	~14 L/70 kg
Total body water	~42 L/70 kg

Interpreting Vd:

Vd	Meaning	Drug Examples
~3–5 L	Stays in plasma	Heparin, warfarin
~14 L	Distributes into ECF	Aminoglycosides
>42 L	Concentrates in tissues	Digoxin (~500 L), chloroquine
Hundreds of L	Extensive tissue binding	Amiodarone

USMLE Pearl: High Vd = drug is mostly in tissues = dialysis is ineffective at removing it.

B. Clearance (CL)

Definition: The factor that predicts the rate of elimination in relation to drug concentration.

EQUATION 2:

           Rate of elimination
CL  =  ────────────────────────
                  C

  Rearranged:

  Rate of elimination  =  CL  ×  C

Clearance is additive across organs:

EQUATION 3:

CL(total)  =  CL(renal)  +  CL(hepatic)  +  CL(other)

"Other" = lungs, blood, muscle
Renal CL = measured from unchanged drug in urine
Hepatic CL = assumed as CL(total) − CL(renal); difficult to measure directly

For first-order drugs, clearance can be estimated as:

EQUATION 4:

          Dose
CL  =  ─────────
          AUC

(This is a calculation convenience only — NOT the definition of clearance. Valid for first-order drugs ONLY.)

First-order elimination: A constant fraction of drug is eliminated per unit time. CL remains constant across clinically relevant concentrations.

SECTION 3: TYPES OF ELIMINATION

A. Capacity-Limited (Michaelis-Menten) Elimination

Also called: Saturable / nonlinear / mixed-order / zero-order (at saturation)

EQUATION 5:

                      Vmax  ×  C
Rate of elimination  =  ─────────────
                         Km  +  C

Parameter	Definition
Vmax	Maximum elimination capacity of the enzyme system
Km	Drug concentration at which elimination rate = 50% of Vmax

Behavior at different concentrations:

C vs Km	Kinetics	Clinical Result
C << Km	First-order (linear)	CL appears constant
C ≈ Km	Mixed order	Transitional
C >> Km	Pseudo-zero-order	Rate ≈ Vmax; constant amount eliminated per unit time

Key rules:

If dosing rate exceeds elimination capacity → steady state is never reached → concentration rises indefinitely
CL has no real meaning (it varies with concentration)
AUC must NOT be used to calculate CL for these drugs

The 3 classic capacity-limited drugs — "PEA":

Phenytoin

Ethanol

Aspirin (at anti-inflammatory/toxic doses)

B. Flow-Dependent (High-Extraction) Elimination

Drug is so efficiently cleared that most is removed on the first pass through the organ
Elimination depends primarily on blood flow, not enzyme capacity
Called "high-extraction drugs"
Plasma protein binding and RBC partitioning can also influence clearance

Extraction Ratio (ER):

           CL(hepatic)
ER  =  ─────────────────
            Q(liver)

Where Q(liver) = hepatic blood flow (~90 L/h/70 kg)

ER	Type	Oral bioavailability	CL depends on
> 0.7	High extraction	Poor (large first-pass)	Blood flow
< 0.3	Low extraction	Good	Enzyme capacity

Examples: Lidocaine, morphine, propranolol, nitroglycerin Clinical implication: Heart failure → ↓ hepatic blood flow → ↓ CL of high-extraction drugs → toxicity risk

C. Large Molecules (Biologics / Therapeutic Proteins)

Shared PK: half-life ~2 weeks
Target-Mediated Drug Disposition (TMDD): When the drug binds and eliminates the target (e.g., T cells), the target contributes to drug clearance
- TMDD active → CL increases → t½ shortens
- As target depletes → CL slows → t½ lengthens
Effect time course mirrors drug concentration changes

SECTION 4: HALF-LIFE (t½)

Definition: Time required for the amount of drug in the body to change by one-half during elimination (or during constant infusion).

EQUATION 6:

           0.7  ×  V
t(1/2)  =  ──────────
                CL

0.7 ≈ ln 2 = 0.693 (exact)
V = volume of distribution
CL = clearance
t½ is a derived/secondary parameter — it depends on both V and CL

t½ changes:

Change	Effect on t½
V increases	t½ increases
CL decreases	t½ increases
V decreases	t½ decreases
CL increases	t½ decreases

Time to steady state:

Half-lives elapsed	% Steady state reached
1	50%
2	75%
3	87.5%
4	93.8%
5	~97% → clinically complete

USMLE Rule: ~4–5 half-lives to reach OR leave steady state.

Classic example — Digoxin in chronic renal failure:

CL ↓ (would lengthen t½)

Vd ALSO ↓ (↓ skeletal muscle mass → less Na⁺/K⁺-ATPase binding sites)

Net result: t½ increase is less than expected from CL change alone

Key lesson: A change in t½ does NOT always reflect a change in drug elimination — always assess V and CL independently

SECTION 5: DRUG ACCUMULATION & ACCUMULATION FACTOR

EQUATION 7:

                              1
Accumulation factor  =  ──────────────────────────
                          1  −  e^(−0.7 × τ/t½)

Where τ (tau) = dosing interval

When dosing interval = 1 half-life:

  Accumulation factor  =  1 / 0.5  =  2

Predicts the ratio of steady-state peak concentration to peak concentration after the first dose
Peak at steady state = (Peak after first dose) × accumulation factor

SECTION 6: BIOAVAILABILITY (F)

Definition: The fraction of unchanged drug reaching systemic circulation after administration by any route.

For IV: F = 1.0 (100%, by definition)

For oral with first-pass:

EQUATION (Bioavailability):

  F  =  F(abs)  ×  (1  −  ER)

Where:

F(abs) = fraction absorbed across the gut wall
ER = hepatic extraction ratio

Routes and bioavailability (Table 3-3):

Route	Bioavailability	Key Feature
IV	100% (by definition)	Most rapid onset
IM	75 to ≤100%	Large volumes feasible; may be painful
SC	75 to ≤100%	Smaller volumes than IM
Oral (PO)	5 to <100%	Most convenient; first-pass effect important
Rectal (PR)	30 to <100%	Less first-pass than oral
Inhalation	5 to <100%	Very rapid onset
Transdermal	80 to ≤100%	Avoids first-pass; prolonged action

Two reasons oral F < 100%:

Incomplete gut wall absorption
First-pass hepatic elimination (portal vein → liver → metabolism before reaching systemic circulation)

High first-pass drugs: nitroglycerin, morphine, propranolol, lidocaine

SECTION 7: TIME COURSE OF DRUG ACTION

A. Effect Site Delay (Biophase)

Plasma concentration ≠ effect site concentration immediately
Drug must distribute to the effect compartment (biophase) before exerting effect
Example: IV digoxin — peak plasma in minutes but full cardiac effect takes ~6 hours (time for myocardial distribution)

B. Slow Turnover (Indirect) Effects

When a drug affects synthesis or degradation of an endogenous substance, the onset of effect is governed by the turnover rate of that substance — NOT the drug's own half-life

Warfarin example:

Warfarin inhibits vitamin K epoxide reductase (VKOR) rapidly

Clinical effect (↑ INR) is delayed because it reflects depletion of the prothrombin complex of clotting factors

Prothrombin complex t½ ≈ 14 hours

This 14-hour t½ governs the rate of INR change — not warfarin's own t½ (~37 h)

C. Schedule-Dependent Effects

Same average steady-state concentration can produce different effects depending on the dosing schedule
Aminoglycoside example (gentamicin):
- Constant infusion → greater renal toxicity
- Intermittent (once-daily) dosing → high peaks saturate renal cortex uptake → less total renal accumulation → less nephrotoxicity
- This exploits a nonlinear, saturable uptake mechanism
- Both approaches may produce the same average steady-state concentration

USMLE Pearl: Once-daily aminoglycoside dosing is preferred — exploits saturable renal uptake to reduce nephrotoxicity while maintaining efficacy (peak-dependent killing).

D. Cumulative Effects

Some effects correlate with total cumulative exposure (AUC) rather than peak concentration
Example: Cytotoxic drugs (cancer chemotherapy) that bind irreversibly to DNA
- Tumor killing = cumulative drug-DNA binding = function of AUC
- AUC is the appropriate PK target for individualizing chemotherapy dosing

SECTION 8: TARGET CONCENTRATION APPROACH — RATIONAL DOSING

Maintenance Dose

At steady state: Rate in = Rate out

EQUATION 8:

  Dosing rate  =  CL  ×  TC

  Full maintenance dose formula:

                     CL  ×  TC  ×  τ
  Maintenance dose  =  ─────────────────
                              F

Where:

CL = clearance (most important PK parameter for maintenance dosing)
TC = target concentration
τ = dosing interval
F = bioavailability (= 1 for IV)

CL is the key parameter for maintenance dosing.

Loading Dose

Used when therapeutic effect is needed rapidly (cannot wait 4–5 t½)

EQUATION 9:

                    V  ×  TC
  Loading dose  =  ──────────
                       F

Where:

V = volume of distribution (key parameter for loading dose)
TC = target concentration
F = bioavailability

Vd is the key parameter for loading dose. Large Vd → large loading dose required. Example: Digoxin — large Vd (~500 L) → loading dose given in divided doses over 12–24 h due to narrow therapeutic index.

SECTION 9: THERAPEUTIC DRUG MONITORING (TDM)

When to Use TDM:

Narrow therapeutic index drugs: digoxin, lithium, phenytoin, aminoglycosides, cyclosporine, vancomycin
Suspected toxicity or treatment failure
Disease states altering PK (renal failure, liver failure, heart failure)
Suspected non-compliance

Sample Timing Rules:

Drug	When to Sample
Most oral drugs	≥ 2 hours after dose (absorption complete)
Digoxin	≥ 6 hours after dose (tissue distribution complete)
Lithium	Just before next dose (trough; ~24 h after last dose)
Aminoglycosides	~1 hour after dose (peak); just before next dose (trough)

Plasma Protein Binding — Is It Clinically Important?

Only free (unbound) drug is pharmacologically active
Common teaching: if drug is displaced from protein → free drug ↑ → effect ↑ → toxicity

BUT — this theory does not hold in an open biological system:

  Protein binding displacement
  → free drug briefly ↑
  → elimination rate ↑ (because CL acts on free drug)
  → after ~4 half-lives, free drug returns to previous steady-state
  → net clinical effect: minimal

A seemingly large shift (e.g., unbound fraction from 1% → 10%) releases < 5% of total body drug into the unbound pool (because < 1/3 of total body drug is bound to plasma proteins even for highly bound drugs like warfarin)
When protein displacement does cause a significant interaction, the displacing drug is also inhibiting clearance — it is the CL change, not the protein binding change, that matters

Clinical relevance of protein binding:

Helps interpret measured drug concentrations
In hypoalbuminemia (liver disease, nephrotic syndrome): total drug concentration ↓, but free (active) concentration is unchanged

Red Blood Cell Binding

Cyclosporine and tacrolimus bind extensively inside RBCs
Whole blood concentration ≈ 50× plasma concentration
Fall in hematocrit → whole blood concentration falls, but pharmacologically active concentration unchanged
Concentrations should be standardized to a reference hematocrit for correct interpretation

SECTION 10: DOSE INDIVIDUALIZATION — PK + PD PARAMETERS NEEDED

Parameter	Type	Role
Clearance (CL)	PK	Determines maintenance dose
Volume of distribution (V)	PK	Determines loading dose
Half-life (t½)	PK (derived)	Determines dosing interval + time to steady state
Bioavailability (F)	PK	Scaling factor for oral/non-IV doses
E_max	PD	Maximum achievable drug effect
C50 (EC50)	PD	Concentration producing 50% of E_max

SECTION 11: DISEASE EFFECTS ON PK

Condition	PK Change	Clinical Consequence
Renal failure	↓ CL(renal)	Drug accumulates; reduce dose or extend interval
Hepatic cirrhosis	↓ CL(hepatic) + ↑ V	t½ can increase threefold or more
Heart failure	↓ hepatic blood flow → ↓ CL	High-extraction drugs accumulate (lidocaine, morphine)
Obesity	↑ V for lipophilic drugs	Prolonged t½
Elderly	↓ renal function (even with normal creatinine)	Reduced CL; digoxin, aminoglycoside accumulation
Neonates	Immature organ CL	Standard adult doses cause toxicity
Renal failure + digoxin	↓ CL AND ↓ V	t½ change less dramatic than expected
Aging + diazepam	CL unchanged; V increases	t½ lengthens with age (not a CL problem)

Creatinine Clearance Estimation (Cockcroft-Gault):

           (140 − Age)  ×  Weight (kg)
CrCl  =  ─────────────────────────────  ×  0.85  (females only)
            72  ×  Serum creatinine (mg/dL)

SECTION 12: ALL FORMULAS — MASTER REFERENCE

─────────────────────────────────────────────────────────────────
 EQ.1   Volume of distribution:
        Vd  =  Amount of drug / C

 EQ.2   Clearance:
        CL  =  Rate of elimination / C
        Rate of elimination  =  CL × C

 EQ.3   Total clearance:
        CL(total)  =  CL(renal) + CL(hepatic) + CL(other)

 EQ.4   Clearance from AUC (first-order only):
        CL  =  Dose / AUC

 EQ.5   Michaelis-Menten kinetics:
        Rate  =  (Vmax × C) / (Km + C)

 EQ.6   Half-life:
        t½  =  (0.7 × V) / CL

 EQ.7   Accumulation factor:
        AF  =  1 / [1 − e^(−0.7 × τ/t½)]

 EQ.8   Maintenance dose:
        Dose(maint)  =  (CL × TC × τ) / F

 EQ.9   Loading dose:
        Dose(load)  =  (V × TC) / F

 EQ.10  Oral bioavailability with first-pass:
        F  =  F(abs) × (1 − ER)

 EQ.11  Cockcroft-Gault CrCl:
        CrCl  =  [(140 − Age) × Weight] / [72 × SCr]
                 × 0.85 (for females)
─────────────────────────────────────────────────────────────────

SECTION 13: HIGH-YIELD USMLE MNEMONICS

Mnemonic / Rule	What It Covers
PEA	Phenytoin, Ethanol, Aspirin = zero-order / capacity-limited
CL = Dose / AUC	First-order drugs only; never use for PEA drugs
4–5 half-lives	Time to reach or leave steady state
Maintenance → CL	CL is the key parameter for maintenance dosing
Loading → V	Vd is the key parameter for loading dose
High Vd → dialysis fails	Drug is in tissues, not in accessible plasma
High-ER + heart failure	Blood flow ↓ → CL ↓ → toxicity
Warfarin delay	INR onset governed by clotting factor t½ (~14 h), not warfarin t½
Aminoglycoside once-daily	Saturates renal uptake → less nephrotoxicity
Hypoalbuminemia	Total concentration ↓, but free (active) concentration unchanged
t½ change ≠ CL change	Always assess V and CL independently (digoxin in renal failure)

Source: Katzung's Basic & Clinical Pharmacology, 16th Edition — Chapter 3

Create a PDF or Word document of these notes for sharing/studying

Reading File

Running Command

mkdir -p /home/daytona/workspace/katzung-ch3-notes && ls /home/daytona/workspace…

Writing File

~/katzung-ch3-notes/generate_notes.js

const {
  Document, Packer, Paragraph, TextRun, Table, TableRow, TableCell,
  HeadingLevel, AlignmentType, BorderStyle, WidthType, ShadingType,
  VerticalAlign, PageNumber, Header, Footer, PageBreak,
  UnderlineType
} = require('docx');
const fs = require('fs');

// ── Colour palette ──────────────────────────────────────────────
const BLUE       = "1F3864";   // dark navy  – main headings
const MED_BLUE   = "2E74B5";   // section headings
const LIGHT_BLUE = "DEEAF1";   // table header shading
const GREEN_BG   = "E2EFDA";   // mnemonic / pearl boxes
const YELLOW_BG  = "FFF2CC";   // equation boxes
const GREY_BG    = "F2F2F2";   // code-style monospace rows
const WHITE      = "FFFFFF";
const RED_TEXT   = "C00000";   // warnings

// ── Helpers ──────────────────────────────────────────────────────
function heading1(text) {
  return new Paragraph({
    heading: HeadingLevel.HEADING_1,
    spacing: { before: 360, after: 120 },
    children: [new TextRun({ text, bold: true, color: BLUE, size: 28 })]
  });
}

function heading2(text) {
  return new Paragraph({
    heading: HeadingLevel.HEADING_2,
    spacing: { before: 240, after: 80 },
    children: [new TextRun({ text, bold: true, color: MED_BLUE, size: 24 })]
  });
}

function heading3(text) {
  return new Paragraph({
    heading: HeadingLevel.HEADING_3,
    spacing: { before: 180, after: 60 },
    children: [new TextRun({ text, bold: true, color: "404040", size: 22 })]
  });
}

function body(text, opts = {}) {
  return new Paragraph({
    spacing: { before: 60, after: 60 },
    children: [new TextRun({ text, size: 20, ...opts })]
  });
}

function bold(text) {
  return body(text, { bold: true });
}

function bullet(text, level = 0) {
  const runs = [];
  // parse **bold** inline
  const parts = text.split(/(\*\*[^*]+\*\*)/g);
  for (const p of parts) {
    if (p.startsWith('**') && p.endsWith('**')) {
      runs.push(new TextRun({ text: p.slice(2, -2), bold: true, size: 20 }));
    } else {
      runs.push(new TextRun({ text: p, size: 20 }));
    }
  }
  return new Paragraph({
    bullet: { level },
    spacing: { before: 40, after: 40 },
    children: runs
  });
}

function eqBox(lines) {
  // Shaded box for equations
  const rows = lines.map(line =>
    new TableRow({
      children: [new TableCell({
        shading: { fill: YELLOW_BG, type: ShadingType.CLEAR },
        margins: { top: 80, bottom: 80, left: 120, right: 120 },
        children: [new Paragraph({
          children: [new TextRun({ text: line, font: "Courier New", size: 20, bold: line.includes('=') })]
        })]
      })]
    })
  );
  return new Table({
    width: { size: 100, type: WidthType.PERCENTAGE },
    borders: {
      top:    { style: BorderStyle.SINGLE, size: 4, color: "B8860B" },
      bottom: { style: BorderStyle.SINGLE, size: 4, color: "B8860B" },
      left:   { style: BorderStyle.SINGLE, size: 4, color: "B8860B" },
      right:  { style: BorderStyle.SINGLE, size: 4, color: "B8860B" },
    },
    rows
  });
}

function pearlBox(lines) {
  const rows = lines.map(line =>
    new TableRow({
      children: [new TableCell({
        shading: { fill: GREEN_BG, type: ShadingType.CLEAR },
        margins: { top: 60, bottom: 60, left: 120, right: 120 },
        children: [new Paragraph({
          children: [new TextRun({ text: line, size: 20, italics: line.startsWith('★') || line.startsWith('▶') })]
        })]
      })]
    })
  );
  return new Table({
    width: { size: 100, type: WidthType.PERCENTAGE },
    borders: {
      top:    { style: BorderStyle.SINGLE, size: 4, color: "375623" },
      bottom: { style: BorderStyle.SINGLE, size: 4, color: "375623" },
      left:   { style: BorderStyle.SINGLE, size: 6, color: "375623" },
      right:  { style: BorderStyle.SINGLE, size: 4, color: "375623" },
    },
    rows
  });
}

function spacer() {
  return new Paragraph({ spacing: { before: 80, after: 80 }, children: [] });
}

function divider() {
  return new Paragraph({
    spacing: { before: 100, after: 100 },
    border: { bottom: { style: BorderStyle.SINGLE, size: 6, color: MED_BLUE } },
    children: []
  });
}

// Generic two-column table
function dataTable(headers, rows, colWidths) {
  const headerRow = new TableRow({
    tableHeader: true,
    children: headers.map((h, i) => new TableCell({
      shading: { fill: LIGHT_BLUE, type: ShadingType.CLEAR },
      width: { size: colWidths[i], type: WidthType.PERCENTAGE },
      verticalAlign: VerticalAlign.CENTER,
      margins: { top: 60, bottom: 60, left: 80, right: 80 },
      children: [new Paragraph({
        alignment: AlignmentType.CENTER,
        children: [new TextRun({ text: h, bold: true, size: 18, color: BLUE })]
      })]
    }))
  });

  const dataRows = rows.map((row, ri) => new TableRow({
    children: row.map((cell, ci) => new TableCell({
      shading: { fill: ri % 2 === 0 ? WHITE : "F7F9FC", type: ShadingType.CLEAR },
      width: { size: colWidths[ci], type: WidthType.PERCENTAGE },
      margins: { top: 50, bottom: 50, left: 80, right: 80 },
      children: [new Paragraph({
        children: [new TextRun({ text: cell, size: 18 })]
      })]
    }))
  }));

  return new Table({
    width: { size: 100, type: WidthType.PERCENTAGE },
    borders: {
      top:           { style: BorderStyle.SINGLE, size: 4, color: "B0C4DE" },
      bottom:        { style: BorderStyle.SINGLE, size: 4, color: "B0C4DE" },
      left:          { style: BorderStyle.SINGLE, size: 4, color: "B0C4DE" },
      right:         { style: BorderStyle.SINGLE, size: 4, color: "B0C4DE" },
      insideH:       { style: BorderStyle.SINGLE, size: 2, color: "D0D8E4" },
      insideV:       { style: BorderStyle.SINGLE, size: 2, color: "D0D8E4" },
    },
    rows: [headerRow, ...dataRows]
  });
}

// ── Title page block ─────────────────────────────────────────────
function titleBlock() {
  return [
    new Paragraph({
      alignment: AlignmentType.CENTER,
      spacing: { before: 480, after: 160 },
      children: [new TextRun({ text: "PHARMACOKINETICS & PHARMACODYNAMICS", bold: true, size: 40, color: BLUE })]
    }),
    new Paragraph({
      alignment: AlignmentType.CENTER,
      spacing: { before: 80, after: 80 },
      children: [new TextRun({ text: "Rational Dosing & the Time Course of Drug Action", size: 28, color: MED_BLUE, italics: true })]
    }),
    new Paragraph({
      alignment: AlignmentType.CENTER,
      spacing: { before: 80, after: 80 },
      children: [new TextRun({ text: "Chapter 3", bold: true, size: 24, color: "404040" })]
    }),
    new Paragraph({
      alignment: AlignmentType.CENTER,
      spacing: { before: 40, after: 40 },
      children: [new TextRun({ text: "Katzung's Basic & Clinical Pharmacology, 16th Edition", size: 22, italics: true, color: "606060" })]
    }),
    new Paragraph({
      alignment: AlignmentType.CENTER,
      spacing: { before: 40, after: 240 },
      children: [new TextRun({ text: "USMLE First Aid  |  MBBS Level Study Notes", size: 20, color: "808080" })]
    }),
    divider(),
    spacer()
  ];
}

// ── Build document ───────────────────────────────────────────────
const children = [
  ...titleBlock(),

  // ── SECTION 1 ────────────────────────────────────────────────
  heading1("SECTION 1: CORE FRAMEWORK"),
  body("Goal of therapeutics: Maximum beneficial effect + minimal adverse effects.", { bold: true }),
  spacer(),
  body("The dose-effect relationship is divided into two domains:", { bold: true }),
  spacer(),

  dataTable(
    ["Domain", "Governs", "Key Parameters"],
    [
      ["Pharmacokinetics (PK)", "Dose  →  Concentration", "Input, Distribution, Elimination"],
      ["Pharmacodynamics (PD)", "Concentration  →  Effect", "E_max, C50 / EC50"],
    ],
    [30, 40, 30]
  ),
  spacer(),
  bullet("Concentration is the critical link between PK and PD — focus of the Target Concentration Approach."),
  bullet("**Target Concentration (TC):** Drug concentration that best balances beneficial vs. adverse effects."),
  bullet("Example: Digoxin — 1 ng/mL for heart failure; 2 ng/mL for atrial fibrillation."),
  spacer(),
  divider(),

  // ── SECTION 2 ────────────────────────────────────────────────
  heading1("SECTION 2: THE TWO PRIMARY PK PARAMETERS"),

  heading2("A. Volume of Distribution (Vd)"),
  body("Definition: The apparent volume needed to contain the total amount of drug in the body at the same concentration as measured in blood or plasma."),
  spacer(),

  eqBox([
    "EQUATION 1 — Volume of Distribution",
    "",
    "             Amount of drug in body",
    "  Vd  =  ----------------------------",
    "               Concentration (C)",
    "",
    "  C may be: blood (Cb), plasma (Cp), or unbound free water (Cu)",
  ]),
  spacer(),
  bullet("Vd is **apparent** — it does NOT represent a real anatomical space."),
  bullet("Vd often exceeds any physical body volume because drugs concentrate in tissues."),
  spacer(),

  body("Physical Reference Volumes (Table 3-2):", { bold: true }),
  dataTable(
    ["Compartment", "Volume (L/70 kg)"],
    [
      ["Plasma", "~2.8 L  (0.04 L/kg)"],
      ["Blood", "~5.6 L"],
      ["Extracellular fluid", "~14 L"],
      ["Total body water", "~42 L"],
    ],
    [50, 50]
  ),
  spacer(),

  body("Interpreting Vd:", { bold: true }),
  dataTable(
    ["Vd", "Meaning", "Examples"],
    [
      ["~3–5 L",      "Stays in plasma",            "Heparin, warfarin"],
      ["~14 L",       "Distributes to ECF",          "Aminoglycosides"],
      [">42 L",       "Concentrates in tissues",     "Digoxin (~500 L), Chloroquine"],
      ["Hundreds of L","Extensive tissue binding",   "Amiodarone"],
    ],
    [25, 45, 30]
  ),
  spacer(),
  pearlBox([
    "★  USMLE PEARL: High Vd = drug mostly in tissues = dialysis is INEFFECTIVE at removing it.",
  ]),
  spacer(),

  heading2("B. Clearance (CL)"),
  body("Definition: The factor that predicts the rate of drug elimination relative to drug concentration."),
  spacer(),

  eqBox([
    "EQUATION 2 — Clearance",
    "",
    "           Rate of elimination",
    "  CL  =  -----------------------",
    "                   C",
    "",
    "  Rearranged:  Rate of elimination  =  CL  x  C",
  ]),
  spacer(),

  eqBox([
    "EQUATION 3 — Total (Additive) Clearance",
    "",
    "  CL(total)  =  CL(renal)  +  CL(hepatic)  +  CL(other)",
    "",
    "  'Other' includes lungs, blood, muscle",
    "  Renal CL    = measured from unchanged drug in urine",
    "  Hepatic CL  = assumed = CL(total) - CL(renal)",
  ]),
  spacer(),

  eqBox([
    "EQUATION 4 — Clearance from AUC  (First-Order Drugs ONLY)",
    "",
    "              Dose",
    "  CL  =  ----------",
    "              AUC",
    "",
    "  NOTE: Calculation convenience only — NOT the definition of clearance.",
    "  DO NOT use for phenytoin, ethanol, or aspirin.",
  ]),
  spacer(),
  bullet("First-order elimination: a constant FRACTION of drug is eliminated per unit time; CL remains constant."),
  spacer(),
  divider(),

  // ── SECTION 3 ────────────────────────────────────────────────
  heading1("SECTION 3: TYPES OF ELIMINATION"),

  heading2("A. Capacity-Limited (Michaelis-Menten) Elimination"),
  body("Also called: Saturable / nonlinear / mixed-order / zero-order (at saturation)"),
  spacer(),

  eqBox([
    "EQUATION 5 — Michaelis-Menten Kinetics",
    "",
    "                       Vmax  x  C",
    "  Rate of elimination = ----------",
    "                        Km  +  C",
    "",
    "  Vmax = maximum elimination capacity",
    "  Km   = concentration at which rate = 50% of Vmax",
  ]),
  spacer(),

  dataTable(
    ["C vs Km", "Kinetics", "Clinical Result"],
    [
      ["C << Km", "First-order (linear)", "CL appears constant"],
      ["C ≈ Km",  "Mixed order",          "Transitional"],
      ["C >> Km", "Pseudo-zero-order",    "Rate ≈ Vmax; constant AMOUNT eliminated/time"],
    ],
    [25, 30, 45]
  ),
  spacer(),

  pearlBox([
    "★  THE 3 CLASSIC CAPACITY-LIMITED DRUGS — 'PEA'",
    "   P = Phenytoin",
    "   E = Ethanol",
    "   A = Aspirin (at anti-inflammatory / toxic doses)",
    "",
    "▶  If dosing rate exceeds Vmax → steady state is NEVER reached → concentration rises indefinitely.",
    "▶  AUC must NOT be used to calculate CL for PEA drugs.",
  ]),
  spacer(),

  heading2("B. Flow-Dependent (High-Extraction) Elimination"),
  bullet("Drug is cleared so efficiently that most is removed on the **first pass** through the organ."),
  bullet("Elimination depends on **blood flow** to the organ, not enzyme capacity."),
  spacer(),

  eqBox([
    "Extraction Ratio (ER)",
    "",
    "           CL(hepatic)",
    "  ER  =  ----------------",
    "           Q(liver)",
    "",
    "  Q(liver) = hepatic blood flow (~90 L/h/70 kg)",
  ]),
  spacer(),

  dataTable(
    ["ER", "Type", "Oral Bioavailability", "CL depends on"],
    [
      ["> 0.7", "High extraction", "Poor — large first-pass",   "Blood flow"],
      ["< 0.3", "Low extraction",  "Good — minimal first-pass", "Enzyme capacity"],
    ],
    [15, 25, 35, 25]
  ),
  spacer(),
  pearlBox([
    "★  High-extraction drug examples: Lidocaine, Morphine, Propranolol, Nitroglycerin",
    "▶  Heart failure → reduced hepatic blood flow → CL falls → toxicity risk increases.",
  ]),
  spacer(),

  heading2("C. Large Molecules (Biologics / Therapeutic Proteins)"),
  bullet("Shared PK: half-life approximately 2 weeks."),
  bullet("**Target-Mediated Drug Disposition (TMDD):** Drug binds and eliminates the target (e.g., T cells); target contributes to drug CL."),
  bullet("When TMDD is active: CL increases → t½ shortens."),
  bullet("As target is depleted: CL slows → t½ lengthens."),
  bullet("Effect time course mirrors changes in drug concentration."),
  spacer(),
  divider(),

  // ── SECTION 4 ────────────────────────────────────────────────
  heading1("SECTION 4: HALF-LIFE (t½)"),
  body("Definition: Time required for the amount of drug in the body to change by one-half during elimination (or during constant infusion)."),
  spacer(),

  eqBox([
    "EQUATION 6 — Half-Life",
    "",
    "            0.7  x  V",
    "  t½  =  ─────────────",
    "               CL",
    "",
    "  0.7 = approximation of ln(2) = 0.693",
    "  V   = volume of distribution",
    "  CL  = clearance",
    "",
    "  t½ is a DERIVED parameter — it depends on BOTH V and CL.",
  ]),
  spacer(),

  body("Effect of changes on t½:", { bold: true }),
  dataTable(
    ["Change", "Effect on t½"],
    [
      ["V increases", "t½ increases"],
      ["CL decreases", "t½ increases"],
      ["V decreases", "t½ decreases"],
      ["CL increases", "t½ decreases"],
    ],
    [50, 50]
  ),
  spacer(),

  body("Time to Steady State:", { bold: true }),
  dataTable(
    ["Half-lives elapsed", "% Steady state reached", "% Remaining after stopping"],
    [
      ["1", "50%",   "50%"],
      ["2", "75%",   "25%"],
      ["3", "87.5%", "12.5%"],
      ["4", "93.8%", "6.2%"],
      ["5", "~97%  ← clinically complete", "~3%"],
    ],
    [30, 40, 30]
  ),
  spacer(),

  pearlBox([
    "★  USMLE RULE: ~4-5 half-lives to reach OR leave steady state.",
    "",
    "▶  Classic example — Digoxin in chronic renal failure:",
    "   CL is reduced (would lengthen t½).",
    "   BUT Vd is ALSO reduced (decreased skeletal muscle mass → less Na+/K+-ATPase binding).",
    "   Net result: t½ increase is LESS than expected from CL change alone.",
    "",
    "▶  KEY LESSON: A change in t½ does NOT always = a change in elimination.",
    "   Always assess V and CL independently.",
  ]),
  spacer(),
  divider(),

  // ── SECTION 5 ────────────────────────────────────────────────
  heading1("SECTION 5: DRUG ACCUMULATION & ACCUMULATION FACTOR"),
  spacer(),

  eqBox([
    "EQUATION 7 — Accumulation Factor",
    "",
    "                              1",
    "  Accum. factor  =  ─────────────────────────",
    "                      1  -  e^(-0.7 x tau/t½)",
    "",
    "  tau = dosing interval",
    "",
    "  When dosing interval = 1 half-life:",
    "  Accumulation factor  =  1 / 0.5  =  2",
  ]),
  spacer(),
  bullet("Predicts ratio of steady-state peak concentration to peak after the first dose."),
  bullet("Peak at steady state = (Peak after 1st dose) x accumulation factor."),
  spacer(),
  divider(),

  // ── SECTION 6 ────────────────────────────────────────────────
  heading1("SECTION 6: BIOAVAILABILITY (F)"),
  body("Definition: Fraction of unchanged drug reaching systemic circulation after administration by any route."),
  spacer(),

  eqBox([
    "Bioavailability with First-Pass Effect",
    "",
    "  F  =  F(abs)  x  (1  -  ER)",
    "",
    "  F(abs) = fraction absorbed across gut wall",
    "  ER     = hepatic extraction ratio",
    "",
    "  For IV route:  F = 1.0 (100%, by definition)",
  ]),
  spacer(),

  body("Routes and Bioavailability (Table 3-3):", { bold: true }),
  dataTable(
    ["Route", "Bioavailability", "Key Feature"],
    [
      ["IV",           "100% (by definition)",  "Most rapid onset"],
      ["IM",           "75 to ≤100%",           "Large volumes feasible; may be painful"],
      ["SC",           "75 to ≤100%",           "Smaller volumes than IM"],
      ["Oral (PO)",    "5 to <100%",            "Most convenient; first-pass effect important"],
      ["Rectal (PR)",  "30 to <100%",           "Less first-pass than oral"],
      ["Inhalation",   "5 to <100%",            "Very rapid onset"],
      ["Transdermal",  "80 to ≤100%",           "Avoids first-pass; prolonged action"],
    ],
    [20, 28, 52]
  ),
  spacer(),
  body("Two reasons oral F < 100%:", { bold: true }),
  bullet("1. Incomplete absorption across the gut wall."),
  bullet("2. First-pass hepatic elimination (gut → portal vein → liver → metabolism before systemic circulation)."),
  spacer(),
  pearlBox([
    "★  High first-pass drugs (low oral bioavailability): Nitroglycerin, Morphine, Propranolol, Lidocaine.",
  ]),
  spacer(),
  divider(),

  // ── SECTION 7 ────────────────────────────────────────────────
  heading1("SECTION 7: TIME COURSE OF DRUG ACTION"),

  heading2("A. Effect Site Delay (Biophase)"),
  bullet("Plasma concentration does NOT equal effect site concentration immediately."),
  bullet("Drug must distribute to the effect compartment (biophase) before exerting effect."),
  bullet("Example: IV digoxin — plasma peak within minutes; full cardiac effect takes ~6 hours (myocardial distribution)."),
  spacer(),

  heading2("B. Slow Turnover / Indirect Effects"),
  bullet("When a drug alters synthesis or degradation of an endogenous substance, onset of effect is governed by the turnover rate of THAT SUBSTANCE — not the drug's own t½."),
  spacer(),
  pearlBox([
    "★  WARFARIN EXAMPLE:",
    "   Warfarin inhibits vitamin K epoxide reductase (VKOR) rapidly.",
    "   BUT clinical effect (INR rise) is delayed — reflects depletion of prothrombin complex.",
    "   Prothrombin complex t½ ≈ 14 hours.",
    "   This 14-hour t½ governs INR change — NOT warfarin's own t½ (~37 h).",
  ]),
  spacer(),

  heading2("C. Schedule-Dependent Effects"),
  bullet("Same average steady-state concentration can produce different toxicity profiles depending on the dosing schedule."),
  spacer(),
  pearlBox([
    "★  AMINOGLYCOSIDE EXAMPLE (Gentamicin):",
    "   Constant infusion  → greater renal toxicity.",
    "   Intermittent once-daily dosing → high peaks SATURATE renal cortex uptake",
    "                                  → less total renal accumulation → less nephrotoxicity.",
    "▶  Once-daily aminoglycoside dosing is preferred (exploits saturable renal uptake).",
  ]),
  spacer(),

  heading2("D. Cumulative Effects"),
  bullet("Some effects correlate with total cumulative exposure (AUC), not peak concentrations."),
  bullet("Example: Cytotoxic chemotherapy drugs that bind irreversibly to DNA — tumor killing is a function of AUC."),
  spacer(),
  divider(),

  // ── SECTION 8 ────────────────────────────────────────────────
  heading1("SECTION 8: TARGET CONCENTRATION APPROACH — RATIONAL DOSING"),

  heading2("Maintenance Dose"),
  body("At steady state:  Rate in  =  Rate out"),
  spacer(),

  eqBox([
    "EQUATION 8 — Maintenance Dose",
    "",
    "  Dosing rate  =  CL  x  TC",
    "",
    "  Full formula:",
    "",
    "                       CL  x  TC  x  tau",
    "  Maintenance dose  = --------------------",
    "                               F",
    "",
    "  CL  = clearance  (KEY parameter for maintenance dosing)",
    "  TC  = target concentration",
    "  tau = dosing interval",
    "  F   = bioavailability (= 1 for IV)",
  ]),
  spacer(),

  heading2("Loading Dose"),
  body("Used when rapid therapeutic effect is needed and you cannot wait 4–5 half-lives."),
  spacer(),

  eqBox([
    "EQUATION 9 — Loading Dose",
    "",
    "                     V  x  TC",
    "  Loading dose  =  -----------",
    "                        F",
    "",
    "  V   = volume of distribution  (KEY parameter for loading dose)",
    "  TC  = target concentration",
    "  F   = bioavailability",
  ]),
  spacer(),
  pearlBox([
    "★  Digoxin loading ('digitalization'): large Vd (~500 L) → large loading dose.",
    "   Given in divided doses over 12-24 h due to narrow therapeutic index.",
  ]),
  spacer(),
  divider(),

  // ── SECTION 9 ────────────────────────────────────────────────
  heading1("SECTION 9: THERAPEUTIC DRUG MONITORING (TDM)"),

  heading2("When to Use TDM"),
  bullet("Narrow therapeutic index drugs: digoxin, lithium, phenytoin, aminoglycosides, cyclosporine, vancomycin."),
  bullet("Suspected toxicity or treatment failure."),
  bullet("Disease states altering PK (renal failure, liver failure, heart failure)."),
  bullet("Suspected non-compliance."),
  spacer(),

  heading2("Sample Timing Rules"),
  dataTable(
    ["Drug", "When to Sample"],
    [
      ["Most oral drugs",    "≥ 2 hours after dose (absorption complete)"],
      ["Digoxin",           "≥ 6 hours after dose (tissue distribution complete)"],
      ["Lithium",           "Just before next dose (trough; ~24 h after last dose)"],
      ["Aminoglycosides",   "~1 h after dose (peak);  just before next dose (trough)"],
    ],
    [30, 70]
  ),
  spacer(),

  heading2("Plasma Protein Binding — Is It Clinically Important?"),
  bullet("Only FREE (unbound) drug is pharmacologically active."),
  bullet("Common teaching: protein displacement → free drug increases → toxicity."),
  bullet("This theory does NOT hold in the body (an open system):"),
  spacer(),

  eqBox([
    "Protein binding displacement alone does NOT cause sustained toxicity:",
    "",
    "  Displacement  →  free drug briefly increases",
    "               →  elimination rate increases (CL acts on free drug)",
    "               →  after ~4 half-lives, free drug returns to previous steady-state",
    "               →  net clinical effect: minimal",
    "",
    "  When displacement DOES matter: the displacing drug is ALSO inhibiting CL.",
    "  It is the change in CL — not protein binding — that causes the interaction.",
  ]),
  spacer(),

  pearlBox([
    "★  Hypoalbuminemia (liver disease, nephrotic syndrome):",
    "   Total drug concentration is LOW, but free (active) concentration is UNCHANGED.",
    "   Do not automatically increase the dose.",
  ]),
  spacer(),

  heading2("Red Blood Cell Binding"),
  bullet("Cyclosporine and tacrolimus bind extensively inside RBCs."),
  bullet("Whole blood concentration ≈ 50x plasma concentration."),
  bullet("Fall in hematocrit → whole blood concentration falls, but active concentration unchanged."),
  spacer(),
  divider(),

  // ── SECTION 10 ───────────────────────────────────────────────
  heading1("SECTION 10: DOSE INDIVIDUALIZATION — PK + PD PARAMETERS"),

  dataTable(
    ["Parameter", "Type", "Role in Dosing"],
    [
      ["Clearance (CL)",        "PK",         "Determines MAINTENANCE dose"],
      ["Volume of distribution (V)", "PK",    "Determines LOADING dose"],
      ["Half-life (t½)",        "PK (derived)","Determines dosing interval + time to steady state"],
      ["Bioavailability (F)",   "PK",         "Scaling factor for oral / non-IV doses"],
      ["E_max",                 "PD",         "Maximum achievable drug effect"],
      ["C50 (EC50)",            "PD",         "Concentration producing 50% of E_max"],
    ],
    [28, 14, 58]
  ),
  spacer(),
  divider(),

  // ── SECTION 11 ───────────────────────────────────────────────
  heading1("SECTION 11: DISEASE EFFECTS ON PK"),

  dataTable(
    ["Condition", "PK Change", "Clinical Consequence"],
    [
      ["Renal failure",             "↓ CL(renal)",               "Drug accumulates; reduce dose or extend interval"],
      ["Hepatic cirrhosis",         "↓ CL(hepatic) + ↑ V",       "t½ can increase threefold or more"],
      ["Heart failure",             "↓ hepatic blood flow → ↓ CL","High-extraction drugs accumulate (lidocaine, morphine)"],
      ["Obesity",                   "↑ V for lipophilic drugs",   "Prolonged t½"],
      ["Elderly",                   "↓ renal CL (even normal Cr)","Digoxin, aminoglycoside accumulation"],
      ["Neonates / Infants",        "Immature organ CL",          "Standard adult doses cause toxicity"],
      ["Renal failure + Digoxin",   "↓ CL AND ↓ V",              "t½ change less dramatic than expected"],
      ["Aging + Diazepam",          "CL unchanged; V increases",  "t½ lengthens with age — not a CL problem"],
    ],
    [25, 30, 45]
  ),
  spacer(),

  eqBox([
    "EQUATION 11 — Creatinine Clearance (Cockcroft-Gault)",
    "",
    "           (140 - Age)  x  Weight (kg)",
    "  CrCl  = ---------------------------------   x  0.85  (for females only)",
    "            72  x  Serum creatinine (mg/dL)",
  ]),
  spacer(),
  divider(),

  // ── SECTION 12 ───────────────────────────────────────────────
  heading1("SECTION 12: MASTER FORMULA REFERENCE"),

  eqBox([
    "ALL KEY EQUATIONS — CHAPTER 3",
    "──────────────────────────────────────────────────────────────",
    "",
    "EQ.1  Volume of Distribution:",
    "        Vd  =  Amount of drug in body  /  C",
    "",
    "EQ.2  Clearance:",
    "        CL  =  Rate of elimination  /  C",
    "        Rate of elimination  =  CL  x  C",
    "",
    "EQ.3  Total Clearance:",
    "        CL(total)  =  CL(renal)  +  CL(hepatic)  +  CL(other)",
    "",
    "EQ.4  Clearance from AUC (first-order only):",
    "        CL  =  Dose  /  AUC",
    "",
    "EQ.5  Michaelis-Menten kinetics:",
    "        Rate  =  (Vmax x C)  /  (Km + C)",
    "",
    "EQ.6  Half-life:",
    "        t½  =  (0.7  x  V)  /  CL",
    "",
    "EQ.7  Accumulation Factor:",
    "        AF  =  1  /  [1  -  e^(-0.7 x tau/t½)]",
    "",
    "EQ.8  Maintenance Dose:",
    "        Dose(maint)  =  (CL  x  TC  x  tau)  /  F",
    "",
    "EQ.9  Loading Dose:",
    "        Dose(load)  =  (V  x  TC)  /  F",
    "",
    "EQ.10 Oral Bioavailability with First-Pass:",
    "        F  =  F(abs)  x  (1  -  ER)",
    "",
    "EQ.11 Cockcroft-Gault CrCl:",
    "        CrCl  =  [(140 - Age) x Weight]  /  [72 x SCr]  x 0.85 (females)",
    "──────────────────────────────────────────────────────────────",
    "",
    "  MAINTENANCE DOSE  →  driven by  CL   (clearance)",
    "  LOADING DOSE      →  driven by  V    (volume of distribution)",
    "  TIME TO PLATEAU   →  driven by  t½   (half-life)",
    "  DOSE ADJUSTMENT   →  driven by  F    (bioavailability)",
  ]),
  spacer(),
  divider(),

  // ── SECTION 13 ───────────────────────────────────────────────
  heading1("SECTION 13: HIGH-YIELD USMLE MNEMONICS"),

  dataTable(
    ["Mnemonic / Rule", "What It Covers"],
    [
      ["PEA",                    "Phenytoin, Ethanol, Aspirin = zero-order / capacity-limited kinetics"],
      ["CL = Dose / AUC",        "First-order drugs only — NEVER use for PEA drugs"],
      ["4-5 half-lives",         "Time to reach or leave steady state"],
      ["Maintenance → CL",       "Clearance is the key parameter for maintenance dosing"],
      ["Loading → V",            "Vd is the key parameter for loading dose"],
      ["High Vd → dialysis fails","Drug is in tissues, not accessible in plasma"],
      ["High-ER + heart failure", "Blood flow ↓ → CL ↓ → toxicity (lidocaine, morphine)"],
      ["Warfarin delay",          "INR onset governed by clotting factor t½ (~14 h), not warfarin t½"],
      ["Aminoglycoside once-daily","Saturates renal uptake → less nephrotoxicity"],
      ["Hypoalbuminemia",         "Total concentration ↓, but free (active) concentration unchanged"],
      ["t½ change ≠ CL change",  "Always assess V and CL independently (classic: digoxin in renal failure)"],
    ],
    [35, 65]
  ),
  spacer(),
  divider(),

  // ── Footer note ───────────────────────────────────────────────
  new Paragraph({
    alignment: AlignmentType.CENTER,
    spacing: { before: 240 },
    children: [new TextRun({
      text: "Source: Katzung's Basic & Clinical Pharmacology, 16th Edition — Chapter 3",
      size: 16, italics: true, color: "888888"
    })]
  }),
];

// ── Assemble & write ─────────────────────────────────────────────
const doc = new Document({
  styles: {
    default: {
      document: {
        run: { font: "Calibri", size: 20 }
      }
    }
  },
  sections: [{
    properties: {
      page: {
        margin: { top: 720, bottom: 720, left: 900, right: 900 }
      }
    },
    headers: {
      default: new Header({
        children: [new Paragraph({
          alignment: AlignmentType.RIGHT,
          border: { bottom: { style: BorderStyle.SINGLE, size: 4, color: MED_BLUE } },
          children: [
            new TextRun({ text: "Katzung Ch.3 — PK & PD Notes  |  ", size: 16, color: "888888" }),
            new TextRun({ text: "USMLE / MBBS", size: 16, bold: true, color: MED_BLUE })
          ]
        })]
      })
    },
    footers: {
      default: new Footer({
        children: [new Paragraph({
          alignment: AlignmentType.CENTER,
          children: [
            new TextRun({ text: "Page ", size: 16, color: "888888" }),
            new TextRun({ children: [PageNumber.CURRENT], size: 16, color: "888888" }),
            new TextRun({ text: " of ", size: 16, color: "888888" }),
            new TextRun({ children: [PageNumber.TOTAL_PAGES], size: 16, color: "888888" }),
          ]
        })]
      })
    },
    children
  }]
});

Packer.toBuffer(doc).then(buf => {
  fs.writeFileSync("/home/daytona/workspace/katzung-ch3-notes/Katzung_Ch3_PK_PD_Notes.docx", buf);
  console.log("Done: Katzung_Ch3_PK_PD_Notes.docx created.");
}).catch(err => { console.error(err); process.exit(1); });

Running Command

cd /home/daytona/workspace/katzung-ch3-notes && node generate_notes.js

Running Command

python /home/daytona/skills/docx/scripts/office/validate.py /home/daytona/worksp…

Running Command

ls -lh /home/daytona/workspace/katzung-ch3-notes/Katzung_Ch3_PK_PD_Notes.docx &&…

Your Word document is ready for download:

Katzung Ch3 PK PD Notes

Word Document · DOCX

What's inside the document (22 KB, fully structured):

Header on every page: "Katzung Ch.3 — PK & PD Notes | USMLE / MBBS"
Page numbers in the footer (Page X of Y)
13 sections covering the full chapter
All 11 equations in clearly formatted yellow-shaded boxes using monospace font (Courier New) so fractions and alignment are readable
USMLE pearls in green-shaded highlighted boxes throughout
All tables with alternating row colours and blue headers — Vd reference, bioavailability routes, disease effects on PK, accumulation, steady state, etc.
Master formula reference — all equations in one consolidated box at the end
Mnemonics table at the end for quick revision

The document opens in Microsoft Word, Google Docs, or LibreOffice. If you need a PDF version instead, just let me know and I can convert it.

Generate a presentation (PPT) summarizing the key concepts

Reading File

Writing File

~/katzung-ch3-notes/generate_ppt.js

const pptxgen = require("pptxgenjs");
const pres = new pptxgen();
pres.layout = "LAYOUT_16x9";
pres.title = "Pharmacokinetics & Pharmacodynamics — Katzung Ch.3";
pres.author = "Katzung 16th Edition";

// ── Palette ──────────────────────────────────────────────────────
const NAVY      = "0D1B2A";   // dominant dark
const TEAL      = "1B6CA8";   // accent blue
const CYAN      = "17BEBB";   // highlight
const GOLD      = "F4C542";   // equation accent
const WHITE     = "FFFFFF";
const OFFWHITE  = "F0F4F8";
const LIGHT_BG  = "E8F1FA";
const GREEN     = "2D9E5F";
const RED       = "C0392B";
const GREY      = "7F8C8D";
const DARK_GREY = "2C3E50";

// ── Reusable helpers ─────────────────────────────────────────────
function darkSlide(slide) {
  slide.background = { color: NAVY };
}
function lightSlide(slide) {
  slide.background = { color: OFFWHITE };
}
function tealSlide(slide) {
  slide.background = { color: TEAL };
}

// Accent bar at top
function topBar(slide, color = CYAN) {
  slide.addShape(pres.ShapeType.rect, { x: 0, y: 0, w: 10, h: 0.12, fill: { color } });
}
function leftAccent(slide, color = CYAN) {
  slide.addShape(pres.ShapeType.rect, { x: 0, y: 0, w: 0.12, h: 5.625, fill: { color } });
}
function sectionLabel(slide, text, color = CYAN) {
  slide.addText(text.toUpperCase(), {
    x: 0.2, y: 0.1, w: 9.6, h: 0.3,
    fontSize: 9, bold: true, color, charSpacing: 3, align: "right"
  });
}
function slideTitle(slide, text, color = WHITE, y = 0.3, dark = true) {
  slide.addText(text, {
    x: 0.35, y, w: 9.3, h: 0.65,
    fontSize: 28, bold: true, color,
    fontFace: "Calibri"
  });
}
function subTitle(slide, text, color = CYAN, y = 0.95) {
  slide.addText(text, {
    x: 0.35, y, w: 9.3, h: 0.35,
    fontSize: 13, color, italic: true
  });
}

function eqBox(slide, lines, x, y, w, h) {
  slide.addShape(pres.ShapeType.rect, {
    x, y, w, h,
    fill: { color: "1A1A2E" },
    line: { color: GOLD, width: 1.5 }
  });
  slide.addText(lines.map((l, i) => ({
    text: l,
    options: {
      breakLine: i < lines.length - 1,
      bold: l.includes("=") && !l.startsWith("//"),
      color: l.includes("=") ? GOLD : WHITE,
      fontFace: "Courier New",
      fontSize: 12
    }
  })), { x: x + 0.12, y: y + 0.1, w: w - 0.24, h: h - 0.2 });
}

function pearlBox(slide, lines, x, y, w, h, bgColor = "0F3D2E") {
  slide.addShape(pres.ShapeType.rect, {
    x, y, w, h,
    fill: { color: bgColor },
    line: { color: GREEN, width: 1.5 }
  });
  slide.addText(lines.map((l, i) => ({
    text: l,
    options: {
      breakLine: i < lines.length - 1,
      bold: l.startsWith("★") || l.startsWith("KEY"),
      color: l.startsWith("★") ? CYAN : WHITE,
      fontSize: 12
    }
  })), { x: x + 0.15, y: y + 0.12, w: w - 0.3, h: h - 0.25 });
}

function addTable(slide, headers, rows, x, y, w, rowH = 0.38) {
  const colW = w / headers.length;
  // header row
  headers.forEach((h, i) => {
    slide.addShape(pres.ShapeType.rect, { x: x + i * colW, y, w: colW, h: rowH, fill: { color: TEAL }, line: { color: NAVY, width: 0.5 } });
    slide.addText(h, { x: x + i * colW + 0.05, y: y + 0.05, w: colW - 0.1, h: rowH - 0.1, fontSize: 11, bold: true, color: WHITE, valign: "middle" });
  });
  // data rows
  rows.forEach((row, ri) => {
    const bg = ri % 2 === 0 ? "142339" : "1C3050";
    row.forEach((cell, ci) => {
      slide.addShape(pres.ShapeType.rect, { x: x + ci * colW, y: y + (ri + 1) * rowH, w: colW, h: rowH, fill: { color: bg }, line: { color: "2C4A6E", width: 0.5 } });
      slide.addText(cell, { x: x + ci * colW + 0.05, y: y + (ri + 1) * rowH + 0.04, w: colW - 0.1, h: rowH - 0.08, fontSize: 10, color: WHITE, valign: "middle" });
    });
  });
}

function bullets(slide, items, x, y, w, h, fs = 13) {
  slide.addText(
    items.map((item, i) => ({
      text: typeof item === "string" ? item : item.text,
      options: {
        bullet: { type: "bullet", characterCode: "25B6" },
        breakLine: i < items.length - 1,
        color: typeof item === "object" && item.accent ? CYAN : WHITE,
        bold: typeof item === "object" && item.bold,
        fontSize: fs
      }
    })),
    { x, y, w, h, valign: "top" }
  );
}

// ════════════════════════════════════════════════════════════════
// SLIDE 1 — Title
// ════════════════════════════════════════════════════════════════
{
  const s = pres.addSlide();
  darkSlide(s);
  // Large colored band
  s.addShape(pres.ShapeType.rect, { x: 0, y: 1.6, w: 10, h: 2.6, fill: { color: TEAL }, line: { type: "none" } });
  s.addShape(pres.ShapeType.rect, { x: 0, y: 0, w: 10, h: 0.18, fill: { color: CYAN } });
  s.addShape(pres.ShapeType.rect, { x: 0, y: 5.4, w: 10, h: 0.225, fill: { color: CYAN } });

  s.addText("PHARMACOKINETICS &\nPHARMACODYNAMICS", {
    x: 0.4, y: 1.7, w: 9.2, h: 1.3,
    fontSize: 38, bold: true, color: WHITE, align: "center",
    fontFace: "Calibri", charSpacing: 1
  });
  s.addText("Rational Dosing & the Time Course of Drug Action", {
    x: 0.4, y: 3.05, w: 9.2, h: 0.55,
    fontSize: 18, italic: true, color: GOLD, align: "center"
  });
  s.addText("Chapter 3", {
    x: 0.4, y: 3.65, w: 9.2, h: 0.4,
    fontSize: 14, color: OFFWHITE, align: "center", bold: true
  });
  s.addText("Katzung's Basic & Clinical Pharmacology, 16th Edition", {
    x: 0.4, y: 4.1, w: 9.2, h: 0.35,
    fontSize: 13, italic: true, color: OFFWHITE, align: "center"
  });
  s.addText("USMLE First Aid  |  MBBS Study Notes", {
    x: 0.4, y: 4.95, w: 9.2, h: 0.3,
    fontSize: 11, color: CYAN, align: "center", charSpacing: 2
  });
}

// ════════════════════════════════════════════════════════════════
// SLIDE 2 — Agenda / Roadmap
// ════════════════════════════════════════════════════════════════
{
  const s = pres.addSlide();
  darkSlide(s);
  topBar(s);
  sectionLabel(s, "Overview");
  slideTitle(s, "What We Will Cover");

  const topics = [
    ["01", "Core Framework — PK vs PD"],
    ["02", "Volume of Distribution (Vd)"],
    ["03", "Clearance (CL) & Equations"],
    ["04", "Types of Elimination"],
    ["05", "Half-Life & Steady State"],
    ["06", "Bioavailability & Routes"],
    ["07", "Rational Dosing (Loading & Maintenance)"],
    ["08", "Time Course of Drug Action"],
    ["09", "Therapeutic Drug Monitoring"],
    ["10", "Disease Effects & USMLE Pearls"],
  ];

  const colW = 4.6;
  topics.forEach(([num, text], i) => {
    const col = i < 5 ? 0 : 1;
    const row = i % 5;
    const x = 0.25 + col * (colW + 0.3);
    const y = 1.2 + row * 0.78;
    s.addShape(pres.ShapeType.rect, { x, y, w: colW, h: 0.62, fill: { color: "142339" }, line: { color: TEAL, width: 1 } });
    s.addShape(pres.ShapeType.rect, { x, y, w: 0.52, h: 0.62, fill: { color: TEAL }, line: { type: "none" } });
    s.addText(num, { x, y: y + 0.1, w: 0.52, h: 0.42, fontSize: 16, bold: true, color: WHITE, align: "center" });
    s.addText(text, { x: x + 0.58, y: y + 0.1, w: colW - 0.68, h: 0.42, fontSize: 11, color: WHITE, valign: "middle" });
  });
}

// ════════════════════════════════════════════════════════════════
// SLIDE 3 — Core Framework
// ════════════════════════════════════════════════════════════════
{
  const s = pres.addSlide();
  darkSlide(s);
  topBar(s);
  sectionLabel(s, "Section 1");
  slideTitle(s, "Core Framework: PK vs PD");

  // Flow diagram boxes
  const boxes = [
    { label: "DOSE", x: 0.3, color: TEAL },
    { label: "CONCENTRATION", x: 3.3, color: "8E44AD" },
    { label: "EFFECT", x: 6.5, color: GREEN },
  ];
  boxes.forEach(b => {
    s.addShape(pres.ShapeType.rect, { x: b.x, y: 1.2, w: 2.7, h: 0.8, fill: { color: b.color }, line: { type: "none" }, rectRadius: 0.08 });
    s.addText(b.label, { x: b.x, y: 1.25, w: 2.7, h: 0.7, fontSize: 18, bold: true, color: WHITE, align: "center", valign: "middle" });
  });
  // arrows
  s.addShape(pres.ShapeType.rightArrow, { x: 3.04, y: 1.32, w: 0.35, h: 0.56, fill: { color: GOLD } });
  s.addShape(pres.ShapeType.rightArrow, { x: 6.24, y: 1.32, w: 0.35, h: 0.56, fill: { color: GOLD } });
  // PK bracket
  s.addShape(pres.ShapeType.rect, { x: 0.3, y: 2.15, w: 3.05, h: 0.06, fill: { color: CYAN } });
  s.addText("PHARMACOKINETICS (PK)", { x: 0.3, y: 2.25, w: 3.05, h: 0.35, fontSize: 10, color: CYAN, align: "center", bold: true });
  s.addText("Dose → Concentration", { x: 0.3, y: 2.58, w: 3.05, h: 0.28, fontSize: 10, color: WHITE, align: "center" });
  // PD bracket
  s.addShape(pres.ShapeType.rect, { x: 3.35, y: 2.15, w: 3.2, h: 0.06, fill: { color: GOLD } });
  s.addText("PHARMACODYNAMICS (PD)", { x: 3.35, y: 2.25, w: 3.2, h: 0.35, fontSize: 10, color: GOLD, align: "center", bold: true });
  s.addText("Concentration → Effect", { x: 3.35, y: 2.58, w: 3.2, h: 0.28, fontSize: 10, color: WHITE, align: "center" });

  // Two info boxes
  s.addShape(pres.ShapeType.rect, { x: 0.25, y: 3.0, w: 4.65, h: 1.4, fill: { color: "142339" }, line: { color: CYAN, width: 1 } });
  s.addText("PHARMACOKINETICS", { x: 0.35, y: 3.05, w: 4.45, h: 0.35, fontSize: 12, bold: true, color: CYAN });
  s.addText([
    { text: "Input  |  Distribution  |  Elimination\n", options: { breakLine: true } },
    { text: "Governed by: Vd, CL, t½, F\n", options: { breakLine: true } },
    { text: "Key params: Emax and C50 (EC50)", options: {} },
  ], { x: 0.35, y: 3.42, w: 4.45, h: 0.9, fontSize: 10.5, color: WHITE });

  s.addShape(pres.ShapeType.rect, { x: 5.1, y: 3.0, w: 4.65, h: 1.4, fill: { color: "142339" }, line: { color: GOLD, width: 1 } });
  s.addText("PHARMACODYNAMICS", { x: 5.2, y: 3.05, w: 4.45, h: 0.35, fontSize: 12, bold: true, color: GOLD });
  s.addText([
    { text: "Concentration → Effect\n", options: { breakLine: true } },
    { text: "Emax = maximum possible response\n", options: { breakLine: true } },
    { text: "EC50 = concentration for 50% effect", options: {} },
  ], { x: 5.2, y: 3.42, w: 4.45, h: 0.9, fontSize: 10.5, color: WHITE });

  pearlBox(s, ["★  Target Concentration (TC) = concentration balancing benefit vs. adverse effects"], 0.25, 4.55, 9.5, 0.65);
}

// ════════════════════════════════════════════════════════════════
// SLIDE 4 — Volume of Distribution
// ════════════════════════════════════════════════════════════════
{
  const s = pres.addSlide();
  darkSlide(s);
  topBar(s);
  sectionLabel(s, "Section 2");
  slideTitle(s, "Volume of Distribution (Vd)");

  eqBox(s, [
    "EQUATION 1 — Volume of Distribution",
    "",
    "         Amount of drug in body",
    "  Vd  =  ──────────────────────",
    "              Concentration (C)",
  ], 0.25, 1.1, 4.6, 1.5);

  // Vd reference table
  addTable(s,
    ["Compartment", "Volume (L/70 kg)"],
    [
      ["Plasma", "~2.8 L  (0.04 L/kg)"],
      ["Blood", "~5.6 L"],
      ["ECF", "~14 L"],
      ["Total body water", "~42 L"],
    ],
    5.05, 1.1, 4.7, 0.42
  );

  // Interpretation table
  addTable(s,
    ["Vd", "Drug stays in...", "Example"],
    [
      ["~3–5 L", "Plasma only", "Heparin, Warfarin"],
      ["~14 L",  "ECF", "Aminoglycosides"],
      [">42 L",  "Tissues", "Digoxin (~500 L)"],
      ["100s L", "Deep tissues", "Amiodarone"],
    ],
    0.25, 2.75, 9.5, 0.42
  );

  pearlBox(s, [
    "★  USMLE: High Vd = drug in tissues = dialysis INEFFECTIVE (e.g., digoxin, TCA overdose)",
    "   Vd is APPARENT — it does not represent a real anatomical space",
  ], 0.25, 4.62, 9.5, 0.72);
}

// ════════════════════════════════════════════════════════════════
// SLIDE 5 — Clearance
// ════════════════════════════════════════════════════════════════
{
  const s = pres.addSlide();
  darkSlide(s);
  topBar(s);
  sectionLabel(s, "Section 2");
  slideTitle(s, "Clearance (CL)");

  eqBox(s, [
    "EQ 2 — Clearance",
    "  CL  =  Rate of elimination / C",
    "  Rate of elimination  =  CL  x  C",
  ], 0.25, 1.1, 4.6, 1.1);

  eqBox(s, [
    "EQ 3 — Total Clearance (Additive)",
    "  CL(total) = CL(renal) + CL(hepatic) + CL(other)",
  ], 5.05, 1.1, 4.7, 0.85);

  eqBox(s, [
    "EQ 4 — CL from AUC  [First-Order ONLY]",
    "  CL  =  Dose / AUC",
    "  // NOT valid for phenytoin, ethanol, aspirin",
  ], 5.05, 2.1, 4.7, 0.95);

  bullets(s, [
    { text: "CL is additive across organs (kidney + liver + other)", bold: true },
    "Renal CL = measured from unchanged drug in urine",
    "Hepatic CL = assumed = CL(total) − CL(renal)",
    "First-order: constant FRACTION eliminated per unit time",
  ], 0.3, 2.35, 4.5, 2.0, 12);

  pearlBox(s, [
    "★  CL is the KEY parameter for MAINTENANCE DOSING",
    "   V  is the KEY parameter for LOADING DOSE",
  ], 0.25, 4.62, 9.5, 0.72);
}

// ════════════════════════════════════════════════════════════════
// SLIDE 6 — Types of Elimination
// ════════════════════════════════════════════════════════════════
{
  const s = pres.addSlide();
  darkSlide(s);
  topBar(s);
  sectionLabel(s, "Section 3");
  slideTitle(s, "Types of Elimination");

  // Three boxes
  const types = [
    {
      title: "A. Capacity-Limited",
      color: "6B2737",
      border: RED,
      lines: [
        "= Michaelis-Menten / Saturable",
        "Rate = (Vmax x C) / (Km + C)",
        "C >> Km → pseudo-zero-order",
        "PEA: Phenytoin, Ethanol, Aspirin",
        "AUC must NOT be used for CL",
      ]
    },
    {
      title: "B. Flow-Dependent",
      color: "0F3D2E",
      border: GREEN,
      lines: [
        "= High-extraction drugs",
        "CL depends on blood flow",
        "ER = CL(hepatic) / Q(liver)",
        "Examples: Lidocaine, Morphine",
        "Heart failure → CL falls → toxicity",
      ]
    },
    {
      title: "C. Large Molecules",
      color: "2D1B6B",
      border: "9B59B6",
      lines: [
        "= Biologics / Proteins",
        "t½ ~ 2 weeks (typical)",
        "TMDD: target elimination drives CL",
        "TMDD active → CL ↑ → t½ ↓",
        "Target depleted → CL ↓ → t½ ↑",
      ]
    },
  ];

  types.forEach((t, i) => {
    const x = 0.2 + i * 3.27;
    s.addShape(pres.ShapeType.rect, { x, y: 1.15, w: 3.1, h: 3.4, fill: { color: t.color }, line: { color: t.border, width: 1.5 } });
    s.addShape(pres.ShapeType.rect, { x, y: 1.15, w: 3.1, h: 0.48, fill: { color: t.border }, line: { type: "none" } });
    s.addText(t.title, { x: x + 0.08, y: 1.2, w: 2.95, h: 0.38, fontSize: 12, bold: true, color: WHITE });
    t.lines.forEach((line, li) => {
      s.addText("▸  " + line, { x: x + 0.1, y: 1.73 + li * 0.48, w: 2.9, h: 0.42, fontSize: 10.5, color: WHITE });
    });
  });

  pearlBox(s, [
    "★  PEA drugs: if dosing rate > Vmax → steady state NEVER reached → concentration rises indefinitely",
  ], 0.2, 4.62, 9.6, 0.65);
}

// ════════════════════════════════════════════════════════════════
// SLIDE 7 — Half-Life
// ════════════════════════════════════════════════════════════════
{
  const s = pres.addSlide();
  darkSlide(s);
  topBar(s);
  sectionLabel(s, "Section 4");
  slideTitle(s, "Half-Life (t½)");

  eqBox(s, [
    "EQUATION 6 — Half-Life",
    "",
    "           0.7  x  V",
    "  t½  =  ─────────────",
    "               CL",
    "",
    "  0.7 = ln(2) = 0.693",
    "  t½ is DERIVED — it depends on both V and CL",
  ], 0.25, 1.1, 4.6, 2.3);

  // Steady state table
  addTable(s,
    ["Half-lives (n)", "% Steady State"],
    [
      ["1", "50%"],
      ["2", "75%"],
      ["3", "87.5%"],
      ["4", "93.8%"],
      ["5", "~97%  ✓ clinically complete"],
    ],
    5.05, 1.1, 4.7, 0.42
  );

  bullets(s, [
    { text: "t½ ↑ when V ↑ or CL ↓", bold: true },
    { text: "t½ ↓ when V ↓ or CL ↑", bold: true },
    "~4–5 half-lives to reach OR leave steady state",
    "Digoxin in renal failure: both CL↓ and V↓",
    "→ t½ change is LESS than expected",
  ], 5.05, 3.4, 4.7, 1.85, 12);

  pearlBox(s, [
    "★  A change in t½ does NOT always = a change in elimination.",
    "   Always assess V and CL independently.",
  ], 0.25, 3.5, 4.55, 0.78);

  eqBox(s, [
    "EQ 7 — Accumulation Factor",
    "  AF  =  1 / [1 − e^(−0.7 x tau/t½)]",
    "  Dosed every t½:  AF = 1/0.5 = 2",
  ], 0.25, 4.38, 4.55, 0.98);
}

// ════════════════════════════════════════════════════════════════
// SLIDE 8 — Bioavailability
// ════════════════════════════════════════════════════════════════
{
  const s = pres.addSlide();
  darkSlide(s);
  topBar(s);
  sectionLabel(s, "Section 6");
  slideTitle(s, "Bioavailability (F)");

  eqBox(s, [
    "Bioavailability with First-Pass Effect:",
    "  F  =  F(abs)  x  (1  −  ER)",
    "  ER = CL(hepatic) / Q(liver)",
    "  IV route: F = 1.0  (100% by definition)",
  ], 0.25, 1.1, 5.0, 1.3);

  addTable(s,
    ["Route", "Bioavailability", "Key Feature"],
    [
      ["IV",          "100%",          "Most rapid onset"],
      ["IM / SC",     "75–100%",       "May be painful"],
      ["Oral (PO)",   "5 to <100%",    "First-pass effect"],
      ["Rectal (PR)", "30–100%",       "Less first-pass than PO"],
      ["Inhalation",  "5 to <100%",    "Very rapid onset"],
      ["Transdermal", "80–100%",       "Avoids first-pass; slow"],
    ],
    5.35, 1.1, 4.4, 0.41
  );

  bullets(s, [
    "Two reasons oral F < 100%:",
    { text: "1.  Incomplete gut wall absorption", bold: false },
    { text: "2.  First-pass hepatic elimination", bold: false },
    "",
    "High first-pass drugs (low oral F):",
    { text: "Nitroglycerin, Morphine, Propranolol, Lidocaine", bold: true, accent: true },
  ], 0.3, 2.5, 4.9, 2.4, 12);

  pearlBox(s, [
    "★  High-ER drugs + heart failure:  blood flow ↓ → CL ↓ → toxicity risk ↑",
    "★  ER > 0.7 = flow-limited  |  ER < 0.3 = capacity-limited",
  ], 0.25, 4.6, 9.5, 0.72);
}

// ════════════════════════════════════════════════════════════════
// SLIDE 9 — Rational Dosing
// ════════════════════════════════════════════════════════════════
{
  const s = pres.addSlide();
  darkSlide(s);
  topBar(s);
  sectionLabel(s, "Section 8");
  slideTitle(s, "Rational Dosing: Maintenance & Loading");

  // Two big eq boxes side by side
  eqBox(s, [
    "EQ 8 — MAINTENANCE DOSE",
    "",
    "  Dosing rate  =  CL  x  TC",
    "",
    "              CL  x  TC  x  tau",
    "  Dose  =  ─────────────────────",
    "                      F",
    "",
    "  KEY parameter: CLEARANCE (CL)",
    "  At steady state:  Rate in = Rate out",
  ], 0.25, 1.1, 4.6, 2.8);

  eqBox(s, [
    "EQ 9 — LOADING DOSE",
    "",
    "              V  x  TC",
    "  Dose  =  ───────────",
    "                 F",
    "",
    "  KEY parameter: VOLUME (V)",
    "  Used when rapid effect needed",
    "  Cannot wait 4-5 half-lives",
  ], 5.1, 1.1, 4.65, 2.8);

  addTable(s,
    ["Goal", "Key PK Parameter", "Clinical Example"],
    [
      ["Maintain steady state", "Clearance (CL)", "Digoxin maintenance 0.125 mg/day"],
      ["Rapid therapeutic level", "Volume (V)", "Digoxin loading over 12–24 h"],
      ["Dosing interval", "Half-life (t½)", "Amoxicillin every 8 h (t½ ~1 h)"],
      ["Oral dose adjustment", "Bioavailability (F)", "PO morphine dose 3x IV dose"],
    ],
    0.25, 4.05, 9.5, 0.37
  );

  pearlBox(s, ["★  MAINTENANCE → CL     LOADING → V     INTERVAL → t½     ORAL ADJ → F"], 0.25, 5.18, 9.5, 0.32);
}

// ════════════════════════════════════════════════════════════════
// SLIDE 10 — Time Course of Drug Action
// ════════════════════════════════════════════════════════════════
{
  const s = pres.addSlide();
  darkSlide(s);
  topBar(s);
  sectionLabel(s, "Section 7");
  slideTitle(s, "Time Course of Drug Action");

  const panels = [
    {
      title: "A. Effect Site Delay",
      color: "1A3A5C",
      border: CYAN,
      y: 1.15,
      lines: [
        "Plasma concentration ≠ effect immediately",
        "Drug must distribute to biophase (effect compartment)",
        "Example: IV digoxin — plasma peak in mins,",
        "  full cardiac effect takes ~6 hours",
      ]
    },
    {
      title: "B. Slow Turnover (Warfarin)",
      color: "2D1B00",
      border: GOLD,
      y: 2.85,
      lines: [
        "Warfarin inhibits VKOR rapidly",
        "INR rise is delayed — reflects depletion of",
        "  prothrombin complex (t½ ~14 hours)",
        "Effect delay governed by factor t½, NOT warfarin t½",
      ]
    },
    {
      title: "C. Schedule-Dependent (Aminoglycosides)",
      color: "0F2D1A",
      border: GREEN,
      y: 4.45,
      lines: [
        "Once-daily dosing → high peak saturates renal uptake",
        "→ less total renal accumulation → less nephrotoxicity",
        "Same average SS concentration, different toxicity profile",
      ]
    },
  ];

  panels.forEach(p => {
    s.addShape(pres.ShapeType.rect, { x: 0.25, y: p.y, w: 9.5, h: p.title.includes("Schedule") ? 1.05 : 1.6, fill: { color: p.color }, line: { color: p.border, width: 1.2 } });
    s.addShape(pres.ShapeType.rect, { x: 0.25, y: p.y, w: 0.12, h: p.title.includes("Schedule") ? 1.05 : 1.6, fill: { color: p.border }, line: { type: "none" } });
    s.addText(p.title, { x: 0.45, y: p.y + 0.07, w: 9.2, h: 0.32, fontSize: 12, bold: true, color: p.border });
    s.addText(p.lines.join("  ·  "), { x: 0.45, y: p.y + 0.4, w: 9.1, h: p.title.includes("Schedule") ? 0.55 : 1.1, fontSize: 10.5, color: WHITE });
  });
}

// ════════════════════════════════════════════════════════════════
// SLIDE 11 — TDM & Protein Binding
// ════════════════════════════════════════════════════════════════
{
  const s = pres.addSlide();
  darkSlide(s);
  topBar(s);
  sectionLabel(s, "Section 9");
  slideTitle(s, "Therapeutic Drug Monitoring (TDM)");

  addTable(s,
    ["Drug", "Sample Timing"],
    [
      ["Most oral drugs",    "≥ 2 h after dose  (absorption complete)"],
      ["Digoxin",           "≥ 6 h after dose  (tissue distribution complete)"],
      ["Lithium",           "Just before next dose (trough; ~24 h after last dose)"],
      ["Aminoglycosides",   "Peak: ~1 h post-dose  |  Trough: before next dose"],
    ],
    0.25, 1.1, 9.5, 0.43
  );

  s.addText("Plasma Protein Binding — Is It Clinically Important?", {
    x: 0.25, y: 3.1, w: 9.5, h: 0.35,
    fontSize: 14, bold: true, color: CYAN
  });

  eqBox(s, [
    "Displacement alone does NOT cause sustained toxicity:",
    "  Displacement → free drug ↑ → elimination ↑",
    "  → after ~4 t½, free drug returns to previous steady state",
    "  When displacement matters: displacing drug is ALSO inhibiting CL",
  ], 0.25, 3.5, 9.5, 1.25);

  pearlBox(s, [
    "★  Hypoalbuminemia: total drug concentration ↓, but FREE (active) concentration is UNCHANGED",
    "★  Cyclosporine / Tacrolimus: measure WHOLE BLOOD (binds inside RBCs); ~50x plasma concentration",
  ], 0.25, 4.85, 9.5, 0.72);
}

// ════════════════════════════════════════════════════════════════
// SLIDE 12 — Disease Effects on PK
// ════════════════════════════════════════════════════════════════
{
  const s = pres.addSlide();
  darkSlide(s);
  topBar(s);
  sectionLabel(s, "Section 11");
  slideTitle(s, "Disease Effects on Pharmacokinetics");

  addTable(s,
    ["Condition", "PK Change", "Clinical Consequence"],
    [
      ["Renal failure",        "↓ CL(renal)",            "Drug accumulates → reduce dose / extend interval"],
      ["Hepatic cirrhosis",    "↓ CL(hepatic) + ↑ V",    "t½ increases up to 3× or more"],
      ["Heart failure",        "↓ hepatic blood flow",   "High-extraction drugs accumulate (lidocaine, morphine)"],
      ["Obesity",              "↑ V (lipophilic drugs)",  "Prolonged t½"],
      ["Elderly",              "↓ renal CL (↑ Cr age)",  "Digoxin, aminoglycosides accumulate"],
      ["Neonates",             "Immature organ CL",       "Adult doses cause toxicity"],
    ],
    0.25, 1.1, 9.5, 0.45
  );

  eqBox(s, [
    "Cockcroft-Gault  (Creatinine Clearance Estimation)",
    "",
    "           (140 - Age)  x  Weight (kg)",
    "  CrCl  =  ─────────────────────────────  x  0.85  (females only)",
    "             72  x  Serum creatinine (mg/dL)",
  ], 0.25, 4.0, 9.5, 1.35);
}

// ════════════════════════════════════════════════════════════════
// SLIDE 13 — Master Formula Sheet
// ════════════════════════════════════════════════════════════════
{
  const s = pres.addSlide();
  darkSlide(s);
  topBar(s, GOLD);
  sectionLabel(s, "Quick Reference", GOLD);
  s.addText("MASTER FORMULA SHEET", {
    x: 0.25, y: 0.18, w: 9.5, h: 0.55,
    fontSize: 24, bold: true, color: GOLD, charSpacing: 2
  });

  eqBox(s, [
    "EQ1  Vd  =  Amount / C",
    "EQ2  CL  =  Rate of elimination / C  |  Rate  =  CL x C",
    "EQ3  CL(total) = CL(renal) + CL(hepatic) + CL(other)",
    "EQ4  CL  =  Dose / AUC   [first-order ONLY]",
    "EQ5  Rate  =  (Vmax x C) / (Km + C)   [Michaelis-Menten]",
    "EQ6  t½  =  (0.7 x V) / CL",
    "EQ7  Accum. factor  =  1 / [1 − e^(−0.7 x tau/t½)]",
    "EQ8  Maint. dose  =  (CL x TC x tau) / F",
    "EQ9  Loading dose  =  (V x TC) / F",
    "EQ10 F  =  F(abs) x (1 − ER)",
    "EQ11 CrCl  =  [(140−Age) x Wt] / [72 x SCr]  x 0.85 (females)",
    "",
    "  MAINTENANCE → CL   |   LOADING → V   |   PLATEAU → t½   |   ORAL → F",
  ], 0.2, 0.82, 9.6, 4.55);
}

// ════════════════════════════════════════════════════════════════
// SLIDE 14 — USMLE Mnemonics
// ════════════════════════════════════════════════════════════════
{
  const s = pres.addSlide();
  darkSlide(s);
  topBar(s, GREEN);
  sectionLabel(s, "USMLE High-Yield", GREEN);
  s.addText("HIGH-YIELD MNEMONICS & PEARLS", {
    x: 0.25, y: 0.18, w: 9.5, h: 0.55,
    fontSize: 22, bold: true, color: GREEN, charSpacing: 2
  });

  const pearls = [
    ["PEA", "Phenytoin, Ethanol, Aspirin = zero-order / capacity-limited kinetics"],
    ["4–5 t½", "Time to reach OR leave steady state"],
    ["High Vd", "Drug in tissues → dialysis fails (digoxin, TCA overdose)"],
    ["Warfarin", "INR delay governed by clotting factor t½ (~14 h), NOT warfarin's own t½"],
    ["Aminoglycosides", "Once-daily dosing: saturates renal uptake → less nephrotoxicity"],
    ["Hypoalbuminemia", "Total [drug] ↓, but FREE (active) concentration is unchanged"],
    ["Heart failure", "↓ hepatic blood flow → ↓ CL of high-extraction drugs"],
    ["Digoxin in CRF", "Both CL ↓ and Vd ↓ → t½ change less than expected"],
  ];

  pearls.forEach(([mnem, text], i) => {
    const col = i < 4 ? 0 : 1;
    const row = i % 4;
    const x = 0.25 + col * 4.9;
    const y = 0.9 + row * 1.08;
    s.addShape(pres.ShapeType.rect, { x, y, w: 4.7, h: 0.98, fill: { color: "0F2D1A" }, line: { color: GREEN, width: 1 } });
    s.addShape(pres.ShapeType.rect, { x, y, w: 1.3, h: 0.98, fill: { color: GREEN }, line: { type: "none" } });
    s.addText(mnem, { x: x + 0.04, y: y + 0.1, w: 1.22, h: 0.78, fontSize: 11, bold: true, color: WHITE, align: "center", valign: "middle" });
    s.addText(text, { x: x + 1.38, y: y + 0.08, w: 3.22, h: 0.82, fontSize: 10.5, color: WHITE, valign: "middle" });
  });
}

// ════════════════════════════════════════════════════════════════
// SLIDE 15 — Closing / Summary
// ════════════════════════════════════════════════════════════════
{
  const s = pres.addSlide();
  darkSlide(s);
  s.addShape(pres.ShapeType.rect, { x: 0, y: 0, w: 10, h: 0.18, fill: { color: CYAN } });
  s.addShape(pres.ShapeType.rect, { x: 0, y: 5.44, w: 10, h: 0.18, fill: { color: CYAN } });

  s.addText("KEY TAKEAWAYS", {
    x: 0.25, y: 0.3, w: 9.5, h: 0.5,
    fontSize: 22, bold: true, color: CYAN, charSpacing: 3, align: "center"
  });

  const takeaways = [
    "PK = Dose → Concentration   |   PD = Concentration → Effect",
    "Vd determines LOADING dose;  CL determines MAINTENANCE dose",
    "t½ = 0.7 × V / CL  —  derived from V and CL, not independent",
    "PEA drugs (Phenytoin, Ethanol, Aspirin) show zero-order kinetics",
    "4–5 half-lives to reach or leave steady state",
    "High-extraction drugs: CL tied to blood flow (heart failure = risk)",
    "Protein binding displacement alone ≠ clinical toxicity",
    "TDM: sample timing matters (digoxin ≥6 h; lithium = trough)",
  ];

  takeaways.forEach((t, i) => {
    const y = 0.95 + i * 0.56;
    s.addShape(pres.ShapeType.rect, { x: 0.25, y, w: 9.5, h: 0.5, fill: { color: i % 2 === 0 ? "142339" : "0D1B2A" }, line: { color: TEAL, width: 0.5 } });
    s.addShape(pres.ShapeType.rect, { x: 0.25, y, w: 0.1, h: 0.5, fill: { color: CYAN }, line: { type: "none" } });
    s.addText(t, { x: 0.42, y: y + 0.07, w: 9.2, h: 0.36, fontSize: 11, color: WHITE });
  });

  s.addText("Katzung's Basic & Clinical Pharmacology, 16th Edition — Chapter 3", {
    x: 0.25, y: 5.28, w: 9.5, h: 0.2,
    fontSize: 9, italic: true, color: GREY, align: "center"
  });
}

// ── Write file ───────────────────────────────────────────────────
pres.writeFile({ fileName: "/home/daytona/workspace/katzung-ch3-notes/Katzung_Ch3_PK_PD_Slides.pptx" })
  .then(() => console.log("Done: Katzung_Ch3_PK_PD_Slides.pptx created."))
  .catch(e => { console.error(e); process.exit(1); });

Running Command

cd /home/daytona/workspace/katzung-ch3-notes && node generate_ppt.js

Running Command

python3 -c " import zipfile path = '/home/daytona/workspace/katzung-ch3-notes/Ka…

Your presentation is ready!

Katzung Ch3 PK PD Slides

Presentation · PPTX

What's inside — 15 slides, 365 KB, 16:9 widescreen:

Slide	Content
1	Title slide — dark navy with teal band
2	Roadmap — numbered topic grid (10 topics)
3	Core Framework — PK vs PD flow diagram with labeled arrows
4	Volume of Distribution — equation box + Vd reference tables
5	Clearance — EQ 2, 3, 4 side by side with bullet points
6	Types of Elimination — 3-panel layout (Capacity-Limited / Flow-Dependent / Large Molecules)
7	Half-Life — EQ 6 + steady state table + accumulation factor EQ 7
8	Bioavailability — EQ with first-pass formula + full route table
9	Rational Dosing — Maintenance (EQ 8) vs Loading (EQ 9) side by side
10	Time Course of Drug Action — Effect site delay, Warfarin example, Aminoglycosides
11	TDM — sample timing table + protein binding reality check
12	Disease Effects on PK — table + Cockcroft-Gault formula
13	Master Formula Sheet — all 11 equations in one gold-bordered code box
14	USMLE Mnemonics — 8 high-yield pearl cards (PEA, Warfarin, Aminoglycosides, etc.)
15	Key Takeaways — 8 alternating summary rows

Design: Dark navy background throughout, cyan/gold accents, all equations in Courier New monospace boxes, USMLE pearls in green-bordered boxes. Opens in PowerPoint, Google Slides, or LibreOffice Impress.

This is a shared conversation. Sign in to Orris to start your own chat.